

## Curriculum vitae

### **Prof. em. Dr. med. Rainer Weber**

Ehemaliger Direktor  
Klinik für Infektionskrankheiten und Spitalhygiene  
Universitätsspital Zürich



### **Persönliche Daten**

Geburtsdatum, Heimatort	4. Juli 1955, Menziken AG
Nationalität	CH
Akademische Titel	Prof. em. für Klinische Infektiologie an der Universität Zürich; Dr. med.; DTM&H London (Diploma in Tropical Medicine and Hygiene, London)
Facharzttitel	Innere Medizin FMH und Infektiologie FMH
Familienstand	verheiratet, 2 Söhne
Aktuelle berufliche Adresse	mediX Praxis Altstetten Hohlstrasse 556, 8048 Zürich Telefon: 044 438 80 80 Email: <a href="mailto:rainer.weber@uzh.ch">rainer.weber@uzh.ch</a> oder: <a href="mailto:rainer.weber@medix.ch">rainer.weber@medix.ch</a>

### **Aktuelle Position**

- Arzt (Grundversorger, Internist und Infektiologe) in Gruppenpraxis mediX Altstetten, seit August 2020

**Aus- und Weiterbildung zum Facharzt**

1975	Matura Typ B, Baden AG
1975-1981	Medizinstudium, Universität Zürich
1981	Staatsexamen als Arzt
1982	Doktorand, Prof. A. Uchtenhagen, Psychiatrische Universitätsklinik Zürich
1983	Assistenzarzt Chirurgie, Bezirksspital Brugg
1984	Assistenzarzt Innere Medizin, Klinik Barmelweid AG
1985-1987	Assistenzarzt Innere Medizin, Kantonsspital Aarau
1987-1988	Assistenzarzt Innere Medizin, Med. Poliklinik, Universitätsspital Zürich
1988-1989	Assistenzarzt Infektiologie, Universitätsspital Zürich
1990	Diplomkurs London School of Tropical Medicine and Hygiene
1990-1991	Research Fellow, Parasitic Diseases Branch, Centers for Disease Control, Atlanta, USA

**Akademische Titel und Facharzttitle**

1983	Dr. med. (Empirische Katamnese der Methadonbehandlung Opiatabhängiger bei Hausärzten im Kanton Zürich. Med. Diss. Zürich, 1983, Leitung: Prof. A. Uchtenhagen)
1988	Facharzt Innere Medizin FMH
1990	DTM&H London (Diploma in Tropical Medicine and Hygiene (London School of Tropical Medicine))
1994	Privatdozent Innere Medizin, speziell Infektiologie, Universität Zürich (Die humanpathogenen Mikrosporidien. Habilitationsschrift, Zürich, 1993)
1999	Facharzt Infektiologie FMH (Facharzttitle wurde in der Schweiz erst 1999 geschaffen)
2000	Titularprofessor, Universität Zürich
2005	Ord. Professor <i>ad personam</i> für Klinische Infektiologie, Universität Zürich
2008	Ord. Professor für Klinische Infektiologie, Universität Zürich

**Berufliche Positionen**

1989	Oberarzt Infektiologie, Universitätsspital Zürich
1991-1995	Oberarzt Infektiologie, Universitätsspital Zürich
1995-1997	Leitender Arzt, Infektiologie, Universitätsspital Zürich
1997-2005	Abteilungsleiter <i>ad interim</i> , Klinik für Infektionskrankheiten und Spitalhygiene, Universitätsspital Zürich
2005-7/2020	Klinikdirektor, Klinik für Infektionskrankheiten und Spitalhygiene, Universitätsspital Zürich
2013-2018	Medizinbereichsleiter Innere Medizin-Onkologie, Universitätsspital Zürich
1/2011-7/2015	Prodekan Lehre Klinik, Med. Fakultät, Universität Zürich
8/2015-7/2021	Dekan der Medizinischen Fakultät, Universität Zürich
8/2020-	Arzt bei mediX Altstetten (Grundversorgung, Internist, Infektiologe)

### **Universitäre Lehre**

1989-2020	Lehrbeauftragter, Med. Fakultät, Universität Zürich
1994-2020	<i>Venia legendi</i> Innere Medizin, speziell Infektiologie, Universität Zürich
1995-2020	Examinator Staatsexamen
2005-2020	Fachvertreter Infektiologie, Med. Fakultät, Universität Zürich
2011-2015	Prodekan Lehre Klinik, Med. Fakultät, Universität Zürich
2011-2012	Leitung der Akkreditierung des Medizinstudiums an der Med. Fakultät (Akkreditierung durch Organ für Akkreditierung und Qualitätssicherung der Schweizerischen Hochschulen, OAQ)
2012-2015	Präsident der Schweizerischen Medizinischen Interfakultätskommission (SMIFK)

### **Postgraduale ärztliche Weiterbildung**

1997-2003	Präsident Weiterbildungskommission der Schweiz. Gesellschaft für Infektiologie
1999-2003	Präsident Titelkommission der Schweiz. Gesellschaft für Infektiologie
1999-2003	Präsident Weiterbildungsstättenkommission der Schweiz. Gesellschaft für Infektiologie
2000-2003, 2010-2018	Präsident der Facharzt Prüfungskommission der Schweiz. Gesellschaft für Infektiologie
2003-2014	Delegierter der Schweiz. Gesellschaft für Infektiologie in der UEMS (Union Européenne des Médecins Spécialistes)
2004 und 2010	Leitung der Akkreditierung der FMH Facharzt-Weiterbildung in Infektiologie in der Schweiz (Akkreditierung durch Organ für Akkreditierung und Qualitätssicherung der Schweizerischen Hochschulen, OAQ)

### **Berufsorganisation**

1997-2020	Vorstandsmitglied der Schweiz. Gesellschaft für Infektiologie
2003-2005	Präsident der Schweiz. Gesellschaft für Infektiologie

### **Ethik**

1995-2011	Mitglied der Kantonalen Ethikkommission
-----------	---

### **Andere bildungs-, berufs- und gesundheitspolitische Aktivitäten**

1999-2018	Mitglied Kantonale Aidskommission, Kanton Zürich
2003-2011	Mitglied der Fachgruppe „Klinik und Therapie“ der Eidgenössischen Aidskommission
2012-2015	Mitglied in der Plattform "Zukunft ärztliche Bildung" des Eidg. Departement des Innern und des Bundesamtes für Gesundheit
2012-2015	Mitglied in verschiedenen Themengruppen der Plattform "Zukunft ärztliche Bildung" - Themengruppe "Abschlusszahlen" Humanmedizin - Themengruppe Aus-, Weiter- und Fortbildung

- Themengruppe Finanzierung ärztliche Weiterbildung
  - Themengruppe Interprofessionalität Aus- und Weiterbildung
- 2016- (lebenslang) Wahl zum Einzelmitglied der SAMW (Schweizerische Akademie der Medizinischen Wissenschaften)
- 2015-2021 Mitglied als Dekan der Med. Fakultät Zürich im «Verband der Schweizer Hochschulmedizin», <https://www.unimedsuisse.ch/de>  
seit 2018 Vizepräsident

### Eigene Forschungsinteressen

- HIV infection: Epidemiology, clinical aspects, treatment, pathogenesis
- Non-AIDS complications of HIV infection and treatment
- Microsporidiosis: microbiology and disease
- Cryptosporidiosis: microbiology and disease
- Opportunistic infections: diagnosis, clinical aspects, treatment
- Tick-borne diseases
- Antibiotic use, antibiotic policy, rational use of antimicrobials

### Publikationen und Bibliometrie (Web of Science)

<http://www.researcherid.com/rid/D-5175-2012>

### Wichtige Arbeiten

Weber R, Bryan RT, Owen RL, Wilcox CM, Gorelkin L, Visvesvara GS. Improved light-microscopical detection of microsporidia spores in stool and duodenal aspirates. **New Engl J Med** 1992;326:161-66.

Weber R, Bryan RT, Schwartz DA, Owen RL. Human microsporidial infections. **Clin Microbiol Rev** 1994;7: 426-61.

Weber R, Deplazes P, Flepp M, Mathis A, Baumann R, Sauer B, Kuster H, Lüthy R. Cerebral microsporidiosis due to *Encephalitozoon cuniculi* in a patient with human immunodeficiency virus infection. **New Engl J Med** 1997;336:474-78.

Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, Vernazza P, Sudre P, Flepp M, Furrer HJ, Francioli P, Weber R. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. **Lancet** 1999;353:863-68.

Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, de Wit S, Åkerlund B, Calvo G, d'Arminio Monforte A, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD. Liver-related deaths among persons infected with the human immunodeficiency virus: The D:A:D Study. **Arch Intern Med** [since 2018 JAMA Internal Medicine] 2006;166:1632-41.

Sax H, Bloemberg G, Hasse B, Sommerstein R, Kohler P, Achermann Y, Rössle M, Falk V, Kuster SP, Böttger EC, Weber R. Prolonged outbreak of *Mycobacterium chimaera* infection after open chest heart surgery. **Clin Infect Dis** 2015;61:67-75.

Hasse B, Ledergerber B, Furrer HJ, Battegay M, Hirschel B, Cavassini M, Bertisch B, Bernasconi E, Weber R, and the Swiss HIV Cohort Study. Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study. **Clin Infect Dis** 2011;53:1130-39.

### Publikationsliste

#### A) Original Articles

1. Speich R, Weber R, Vogt P, Kronauer Ch, Lüthy R, Russi EW (1989) Unspezifische und lymphozytäre interstitielle Pneumonie bei HIV-Infektion. Schweiz med Wschr 119:601-12.

2. Bonetti A, Weber R, Vogt M, Wunderli W, Siegenthaler W, Lüthy R (1989) Coinfection with human immunodeficiency virus type 1 and cytomegalovirus in two intravenous drug users. *Ann Intern Med* 111:293-96.
3. Opravil M, Weber R, Ledergerber B, Speich R, Siegenthaler W, Lüthy R (1990) Compliance and laboratory data predict relapse rate of *Pneumocystis carinii* pneumonia during prophylaxis with aerosol pentamidine. *Klin Wochenschr* 68:397-402.
4. Speich R, Weber R, Kronauer Ch, Lüthy R, Russi EW (1990) Prognostic score for *Pneumocystis carinii* pneumonia. *Respiration* 57: 259-63.
5. Weber R, Opravil M, Bloch K, Speich R, Shang Linnenberg H, Kuster H, Kägi M, Jacquier P, Eckert J, Russi EW, Siegenthaler W, Lüthy R (1990) *Pneumocystis carinii*-Pneumonie bei HIV-Infektion: bessere Prognose durch frühe Diagnose. *Deutsch Med Wochenschr* 115:1619-23.
6. Weber R, Ledergerber B, Opravil M, Siegenthaler W, Lüthy R (1990) Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone. *Brit Med J* 301:1362-65.
7. Weber R, Bryan RT, Bishop HS, Wahlquist SP, Sullivan JJ, Juranek DD (1991) Threshold of detection of *Cryptosporidium* oocysts in human stool specimens: Evidence for low sensitivity of current diagnostic methods. *J Clin Microbiol* 29:1323-27.
8. Battegay M, Weber R, Willi J, Eich D, Siegenthaler W, Lüthy R (1991) Exploring the doctor-patient relationship reduces staff stress and enhances empathy when caring for AIDS patients. *Psychother Psychosom* 56:167-73.
9. Weber R, Bonetti A, Jost J, Vogt MW, Spacey B, Siegenthaler W, Lüthy R (1991) Low-dose zidovudine in combination with either acyclovir or lymphoblastoid interferon-alpha in asymptomatic HIV-infected patients: A pilot study. *Infection* 19:395-400.
10. Visvesvara GS, Leitch GJ, Moura HM, Wallace S, Weber R, Bryan T (1991) Culture, electron microscopy, and immunoblot studies on a microsporidian parasite isolated from the urine of a patient with AIDS. *J Protozool* 38:105S-11S (*peer-reviewed original article*).
11. Weber R, Bryan RT, Owen RL, Wilcox CM, Gorelkin L, Visvesvara GS (1992) Improved light-microscopical detection of microsporidia spores in stool and duodenal aspirates. *N Engl J Med* 326:161-66.
12. Schwartz DA, Bryan RT, Hewan-Lowe KO, Visvesvara GS, Weber R, Cali A, Angrit P (1992) Disseminated microsporidiosis (*Encephalitozoon hellem*) and AIDS: Autopsy evidence for respiratory transmission. *Arch Pathol Lab Med* 116:660-68.
13. Speich R, Opravil M, Weber R, Hess T, Lüthy R, Russi E (1992) Prospective evaluation of a prognostic score for *Pneumocystis carinii* pneumonia in HIV infected patients. *Chest* 102:1045-48.
14. Weber R, Müller A, Spycher MA, Opravil M, Ammann R, Briner J (1992) Intestinal *Enterocytozoon bieneusi* microsporidiosis in an HIV-infected patient: Diagnosis by ileo-colonoscopy biopsies and long-term follow-up. *Clin Investig* 70:1019-23.
15. Weber R, Bryan RT, Juranek DD (1992) Improved stool concentration procedure for detection of *Cryptosporidium* oocysts in fecal specimens. *J Clin Microbiol* 30:2869-73.
16. Weber R, Kuster H, Keller R, Bächli T, Spycher MA, Briner J, Russi E, Lüthy R (1992) Pulmonary and intestinal microsporidiosis in a patient with the acquired immunodeficiency syndrome. *Am J Resp Crit Care* 146:1603-05.
17. Schwartz DA, Visvesvara GS, Diesenhouse MC, Weber R, Font RL, Wilson LA, Corrent G, Serdarevic ON, Rosberger DF, Keenan PC, Grossniklaus HE, Hewan-Lowe K, Bryan RT (1993) Pathologic features and immunofluorescent antibody demonstration of ocular microsporidiosis (*Encephalitozoon hellem*) in seven patients with acquired immunodeficiency syndrome. *Am J Ophthalmol* 115:285-92.
18. Grohmann GS, Glass RI, Pereira HG, Monroe SS, Hightower AW, Weber R, Bryan RT (1993) Enteric viruses and diarrhea in HIV-infected patients. *N Engl J Med* 329:14-20.
19. Weber R, Kuster H, Visvesvara GS, Bryan RT, Schwartz DA, Lüthy R (1993) Disseminated *Encephalitozoon hellem* microsporidiosis: Pulmonary colonization, microhematuria, and mild conjunctivitis in a patient with AIDS. *Clin Infect Dis* 17:415-9.

20. Weber R, Sauer B, Lüthy R, Nadal D (1993) Intestinal Enterocytozoon bienewsi and Cryptosporidium coinfection in an HIV-infected child with chronic diarrhea. Clin Infect Dis 17:480-3.
21. Opravil M, Marincek B, Fuchs WA, Weber R, Speich R, Battegay M, Russi EW, Lüthy R (1994) Shortcomings of chest radiography in detecting Pneumocystis carinii pneumonia. JAIDS-J Acq Imm Def 7:39-45.
22. Pfyffer GE, Kissling P, Wirth R, Weber R (1994) Direct detection of Mycobacterium tuberculosis complex in respiratory specimens by a target-amplified test system. J Clin Microbiol 32:918-23.
23. Weber R, Sauer B, Spycher MA, Deplazes P, Keller R, Ammann R, Briner J, Lüthy R (1994) Detection of Septata intestinalis (Microsporidia) in stool specimens, and coprodiagnostic monitoring of successful treatment with albendazole. Clin Infect Dis 19:342-45.
24. Schlatter CE, Kuster H, Lüthy R, Weber R, Russi EW, Opravil M (1994) Sputumuntersuchung zur Diagnostik der Pneumocystis carinii-Pneumonie bei HIV-Infizierten. Deutsch Med Wochenschr 119:1151-55.
25. Schwartz DA, Abou-Elella A, Wilcox CM, Gorelkin L, Visvesvara GS, Thompson SE, Hogan S, Weber R, Bryan RT (1995) The presence of Enterocytozoon bienewsi spores in the lamina propria of small bowel biopsies with no evidence of disseminated microsporidiosis. Arch Pathol Lab Med 119:424-28.
26. Visvesvara GS, Leitch GJ, Pieniazek NJ, Da Silva AJ, Wallace S, Slemenda SB, Weber R, Schwartz DA, Gorelkin L, Wilcox CM, Bryan RT (1995) Short-term in vitro culture and molecular analysis of Enterocytozoon bienewsi. J Eukaryotic Microbiol 42:506-10.
27. Giezendanner S, Wirth HP, Zala G, Weber R, Flury R, Meyenberger Ch (1995) Klinische Manifestationen und Verlauf der Zytomegalievirus-Kolitis bei AIDS-Patienten. Schweiz med Wschr 125:2417-22.
28. Deplazes P, Mathis A, Baumgartner R, Tanner I, Weber R (1996) Immunologic and molecular characterization of Encephalitozoon-like microsporidia isolated from humans and rabbits indicate that Encephalitozoon cuniculi is a zoonotic parasite. Clin Infect Dis 22:557-9.
29. Deplazes P, Mathis A, Müller C, Weber R (1996) Molecular epidemiology of Encephalitozoon cuniculi and first detection of Enterocytozoon bienewsi in faecal samples of pigs. J Eukaryot Microbiol 43: 93S (*peer reviewed original article*).
30. Pfyffer GE, Kissling P, Jahn E, Welscher HM, Salfinger M, Weber R (1996) Diagnostic performance of the amplified Mycobacterium tuberculosis Direct Test in cerebrospinal fluid, other non-respiratory, and respiratory specimens. J Clin Microbiol 34:834-41.
31. Günthard M, Meister Th, Lüthy R, Weber R (1996) Krankheitsbild, Verlauf und Therapie der intestinalen Kryptosporidiose bei HIV-infizierten Personen. Deut Med Wochenschr 121:686-92.
32. Pedersen C, Danner S, Lazzarin A, Glauser MP, Weber R, Katlama C, Barton SE, Lundgren JD, Clumeck N, Dewit S, Sommereijns B, Nielsen JO, Nielsen T, Jensen G, Skinhoj P, Bentsen K, Gerstoft J, Melbye M, Ranki A, Valle SL, Berlureau P, Dietrich M, Schwander S, Goebel FD, Kosmidis J. (1996) Epidemiology of cryptosporidiosis among European AIDS patients. Genitourin Med Sex 72:128-31.
33. Mathis A, Michel M, Kuster H, Müller C, Weber R, Deplazes P (1997) Two Encephalitozoon cuniculi subtypes of human origine are infectious to rabbits. Parasitology 114:29-35.
34. Weber R, Deplazes P, Flepp M, Mathis A, Baumann R, Sauer B, Kuster H, Lüthy R (1997) Cerebral microsporidiosis due to Encephalitozoon cuniculi in a patient with human immunodeficiency virus infection. New Engl J Med 336:474-78.
35. Strässle A, Putnik J, Weber R, Fehr-Merhof A, Wüst J, Pfyffer G (1997) Molecular epidemiology of Mycobacterium tuberculosis isolated from patients of an HIV cohort in Switzerland. J Clin Microbiol 35:374-78.
36. Katzwinkel-Wladarsch S, Deplazes P, Weber R, Löscher T, Rinder H (1997) Comparison of polymerase chain reaction with light microscopy for detection of microsporidia in clinical specimens. Eur J Clin Microbiol Infect Dis 16:7-10.
37. Mathis A, Weber R, Kuster H, Speich R (1997) Simplified sample processing combined with a sensitive one-tube nested PCR for detection of Pneumocystis carinii in respiratory specimens. J Clin Microbiol 35:1691-95.

38. Burchard GD, Kröger J, Hartmann WJ, Moling O, Fleischer K, Hatz C, Gyr K, Weber R, Pichler H, Francioli P, Lüthy R, Nothdurft HD, Weincke T, Dietz K, Kretschmer H (1997) Exchange blood transfusion in severe falciparum malaria: Retrospective evaluation of 61 patients treated with, compared to 63 patients treated without, exchange transfusion. *Trop Med Int Health* 2:733-40.
39. Fleisch F, Burnens A, Weber R, Zbinden R (1998) Helicobacter sp. strain Mainz isolated from cultures of blood from two patients with AIDS. *Clin Infect Dis* 26:526-7.
40. Pusterla N, Weber R, Wolfensberger C, Schär G, Zbinden R, Fierz W, Madigan JE, Dumler JS, Lutz H (1998) Serological evidence of human granulocytic ehrlichiosis in Switzerland. *Eur J Clin Microbiol Infect Dis* 17:207-9.
41. Wanke CA, Mayer H, Weber R, Zbinden R, Watson DA, Acheson D (1998) Enteroaggregative Escherichia coli as a potential cause of diarrheal disease in adults infected with human immunodeficiency virus. *J Infect Dis* 178:185-90.
42. Rinder H, Janitschke K, Aspöck H, da Silva AJ, Deplazes P, Fedorko DP, Franzen C, Heise W, Hüniger F, Lehmacher A, Meyer C, Molina JM, Weber R, Löscher T (1998) Blinded, externally controlled multicenter evaluation of light microscopy and PCR for detection of microsporidia in stool specimens. *J Clin Microbiol* 36:1814-18.
43. Rohner P, Jahn EIM, Ninet B, Ionati C, Weber R, Auckenthaler R, GE Pfyffer (1998) Rapid diagnosis of pulmonary tuberculosis with the Lcx Mycobacterium tuberculosis Assay and comparison with conventional diagnostic techniques. *J Clin Microbiol* 36:3051-4.
44. Ledergerber B, Egger M, Rickenbach M, Weber R (1998) Poverty and prognosis of HIV infection in Switzerland. [Research Letter]. *AIDS* 12:1933-4.
45. Bisset LR, Cone RW, Huber W, Battegay M, Vernazza P, Weber R, Grob PJ, Opravil M (1998) Highly active anti-retroviral therapy during early HIV-infection reverses T-cell activation and maturation abnormalities. *AIDS* 12:2115-23.
46. Deplazes P, Mathis A, van Saanen M, Iten A, Keller R, Tanner I, Glauser M, Weber R, Canning EU (1998) Dual microsporidial infection due to *Vittaforma corneae* and *Encephalitozoon hellem* in a patient with AIDS. *Clin Infect Dis* 27:1521-4.
47. Pfyffer GE, Funke-Kissling P, Rundler E, Weber R (1999) Performance characteristics of the BDProbeTec system for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. *J Clin Microbiol* 37:137-40.
48. Navin TR, Weber R, Rimland D, Roberts JM, Addiss DG, Wahlquist SP, Hogan SE, Vugia DJ, Juranek DD, Schwartz DA, Wilcox CM, Stewart JM, Thompson SE, Bryan RT (1999) Declining CD4(+) T-lymphocyte counts are associated with increased risk of enteric parasitosis and chronic diarrhea: Results of a 3-year longitudinal study. *JAIDS-J Acq Imm Def* 20:154-59.
49. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, Vernazza P, Sudre P, Flepp M, Furrer HJ, Francioli P, Weber R (1999) Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. *Lancet* 353:863-68.
50. Evison J, Jost J, Ledergerber B, Jost L, Strasser F, Weber R (1999) HIV-associated Non-Hodgkin lymphomas: Highly active antiretroviral therapy improves remission rate of chemotherapy. [Research Letter] *AIDS* 13:732-34.
51. Fischer M, Huber W, Kallivroussis A, Ott P, Opravil M, Lüthy R, Weber R, Cone RW (1999) Highly sensitive methods for quantitation of human immunodeficiency virus type 1 RNA from plasma, cells and tissues. *J Clin Microbiol* 37:1260-64.
52. Pusterla N, Leutenegger CM, Huder JB, Weber R, Braun U, Lutz H (1999) Evidence of the Human Granulocytic Ehrlichiosis agent in *Ixodes ricinus* ticks in Switzerland. *J Clin Microbiol* 37:1332-34.
53. Weber R, Ledergerber B, Zbinden R, Altwegg M, Pfyffer G, Spycher MA, Briner J, Opravil M, Meyenberger C, Flepp M (1999) Enteric infections and diarrhea in human immunodeficiency virus-infected persons: Prospective community-based cohort study. *Arch Intern Med* 159:1473-80.
54. Breitenmoser A, Mathis A, Bürgi E, Weber R, Deplazes P (1999) High prevalence of *Enterocytozoon bieneusi* in swine with four genotypes that differ from those identified in humans. *Parasitology* 118:447-53.
55. Biderre C, Mathis A, Deplazes P, Weber R, Ackerstedt J, Méténier G, Vivares C (1999) Molecular karyotype diversity in the microsporidian *Encephalitozoon cuniculi*. *Parasitology* 118:439-45.

56. Mathis A, Tanner I, Weber R, Deplazes P (1999) Genetic and phenotypic intraspecific variation in the microsporidian *Encephalitozoon hellem*. *Int J Parasitol* 29:767-70.
57. Weber R, Christen L, Loy M, Schaller S, Christen S, Joyce CRB, Ledermann U, Ledergerber B, Cone R, Lüthy R, Cohen MR (1999) Randomized, placebo-controlled trial of Chinese herb therapy for HIV-1-infected individuals. *JAIDS-J Acq Imm Def* 22:56-64.
58. Ciernik J, Cone RW, Fehr J, Weber R (1999) Impaired liver function and retroviral activity are risk factors contributing to HIV-associated thrombocytopenia. *AIDS* 13:1913-20.
59. Paris D, Ledergerber B, Weber R, Jost J, Flepp M, Opravil M, Rued C, Zimmerli S (1999) Incidence and predictors of virologic failure of antiretroviral triple drug therapy in a community based cohort. *AIDS Res Hum Retrov* 15:1631-38.
60. Sudre P, Pfyffer GE, Bodmer T, Prod'homme G, Furrer HJ, Bassetti S, Bernasconi E, Matter L, Telenti A, Strässle A, Jacques JP, Weber R (1999) Molecular epidemiology of tuberculosis among HIV-infected persons in Switzerland: A country-wide 9-year cohort study. *Infection* 27:323-30.
61. Leutenegger CM, Pusterla N, Mislin C, Weber R, Lutz H (1999) Molecular evidence of coinfection of ticks with *Borrelia burgdorferi sensu lato* and the human granulocytic ehrlichiosis agent in Switzerland. *J Clin Microbiol* 37:3390-91.
62. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer HJ, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Francioli P, Telenti A (1999) AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy - The Swiss HIV Cohort Study. *JAMA-J Am Med Assoc* 282:2220-26.
63. Knuchel MC, Graf B, Schläpfer E, Kuster H, Fischer M, Weber R, Cone RW (2000) PCR-derived ss DNA probes for fluorescent in situ hybridization to HIV-1 RNA. *J Histochem Cytochem* 48:285-93.
64. Opravil M, Cone RW, Fischer M, Vernazza PL, Bassetti S, Lorenzi P, Bisset LR, Ott P, Huber W, Knuchel MC, Roos M, Lüthy R, Weber R (2000) Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: a randomized trial of double versus triple therapy. *JAIDS-J Acq Imm Def* 23:17-25.
65. Joos B, Fischer M, Opravil M, Ott P, Weber R, Cone RW (2000) Transient rebound of plasma HIV-1 RNA is not followed by repopulation of the lymphoid compartment with HIV-1 infected cells. [Research Letter] *AIDS* 14:752-54.
66. Catanzaro A, Perry S, Clarridge JE, Dunbar S, Goodnight-White S, LoBue PA, Peter C, Pfyffer GE, Sierra MF, Weber R, Woods G, Mathews G, Jonas V, Smith K, Della-Latta P (2000) The Role of Clinical Suspicion in Evaluating a New Diagnostic Test for active Tuberculosis: Results of a Multicenter Prospective Trial. *JAMA-J Am Med Assoc* 283:639-45.
67. Morgan U, Weber R, Xiao L, Sulaiman I, Thompson RCA, Ndiritu W, Lal A, Deplazes P (2000) Molecular characterisation of *Cryptosporidium* isolates obtained from human immunodeficiency virus-infected individuals living in Switzerland, Kenya and the USA. *J Clin Microbiol* 38:1180-83.
68. Kuster H, Opravil M, Ott P, Schlaepfer E, Fischer M, Luethy R, Weber R, Cone RW (2000) Treatment-induced decline of human immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early human immunodeficiency virus-1 infection. *Am J Pathol* 156:1973-86.
69. Knuchel MC, Kuster H, Schlaepfer E, Kallivroussis A, Weber R, Cone RW (2000) Incomplete HIV-1 activation in latently infected U1 cells demonstrated by double in situ hybridization. *Virology* 271:79-89.
70. Fischer M, Günthard HF, Opravil M, Joos B, Huber W, Bisset LR, Ott P, Böni J, Weber R, Cone RW (2000) Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy. *AIDS Res Hum Retrov* 16:1135-40.
71. Ersch J, Speich R, Weber R, Altwegg M, Hauser M (2000) Stellenwert der bronchoalveolären Lavage in der Abklärung HIV-assoziiierter Lungenerkrankungen. *Deut Med Wochenschr* 125:789-793.
72. Weber R, Pusterla N, Loy M, Leutenegger CM, Schär G, Baumann D, Wolfensberger C, Lutz H (2000) Serological and clinical evidence for human granulocytic ehrlichiosis in north-eastern Switzerland. *Schweiz Med Wschr* 130:1462-70.
73. Smith D, Berrey MM, Robertson M, Mehrotra D, Markowitz M, Perrin L, Clumeck N, Lazzarin A, Burckhardt B, Weber R, Corey L, Cooper DA (2000) Virological and immunological effects of



- combination antiretroviral therapy, with zidovudine, lamivudine and indinavir, during primary HIV-1 infection. *J Infect Dis* 182:950-4.
74. Friedl AC, Attenhofer Jost CH, Schalcher C, Amann FW, Flepp M, Jenni R, Linka A, Weber R (2000) Acceleration of proven coronary artery disease among HIV-infected patients on potent antiretroviral therapy. [Research Letter] *AIDS* 14:2790-92.
  75. Couzinet S, Cejas E, Schittny J, Deplazes P, Weber R, Zimmerli S (2000) Phagocytic uptake of *Encephalitozoon cuniculi* by non-professional phagocytes. *Infect Immun* 68:6939-45.
  76. Durrer P, Zbinden R, Fleisch F, Altwegg M, Ledergerber B, Karch H, Weber R (2000) Intestinal infection due to enteroaggregative *Escherichia coli* among Human Immunodeficiency Virus-infected persons. *J Infect Dis* 182:1540-44.
  77. Knuchel M, Speck R, Schlaepfer Nadal E, Ott P, Günthard HF, Opravil M, Cone R, Weber R (2000) Impact of TNF- $\alpha$ , LT- $\alpha$ , Fc $\gamma$ RII, and complement receptor on HIV-1 trapping in lymphoid tissue from HIV-infected patients. *AIDS* 14:2661-69.
  78. Mocroft A, Phillips AN, Miller V, Gatell J, van Lunzen J, Parkin JM, Weber R, Ruge B, Lazzarin A, Lundgren JD on behalf of the EuroSIDA study group (2001) The use of and response to second-line protease inhibitor regimens: Results from the EuroSIDS study. *AIDS* 15:201-09.
  79. Hauser PM, Blanc DS, Sudre P, Senggen Manoloff E, Nahiman A, Bille J, Weber R, Francioli P (2001) Genetic diversity of *Pneumocystis carinii* in HIV-positive and -negative patients as revealed by PCR-SSCP typing. *AIDS* 15:461-66.
  80. Bisset LR, Cone RW, Fischer M, Battegay M, Vernazza PL, Dubs RW, Weber R, Grob PJ, Opravil M (2001) Long-term evaluation of T-cell subset changes after effective combination antiretroviral therapy during asymptomatic HIV-infection. *JAIDS-J Acq Imm Def* 27:266-71.
  81. Furrer HJ, Chan P, Weber R, Egger M (2001) Increased risk of wasting syndrome in HIV-infected travellers: Prospective multicentre study. *T Roy Soc Trop Med H* 95:484-86.
  82. Kronenberg A, Seebach JD, Bossart W, Weber R (2001) Polyclonal proliferation of large granular lymphocytes during cytomegalovirus primary infection in a human immunodeficiency virus-infected patient receiving antiretroviral therapy. *Clin Infect Dis* 33:e34-36.
  83. Friedl AC, Ledergerber B, Flepp M, Hirschel B, Telenti A, Furrer HJ; Bucher HC, Bernasconi E, Weber R (2001) Response to First Protease Inhibitor and Efavirenz Containing Antiretroviral Combination Therapy. The Swiss HIV Cohort Study. *AIDS* 15: 1793-1800.
  84. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, Vernazza P, Lundgren JD, Ledergerber B (2001) HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. *JAMA-J Am Med Assoc* 286:2560-67.
  85. Sax H, Friedl A, Renner E, Steuerwald MH, Weber R (2001) Pilot study of interferon- $\alpha$  with and without amantadine for the treatment of hepatitis C in HIV co-infected individuals on antiretroviral therapy. *Infection* 29:267-70.
  86. Weber R, Bossart W, Cone R, Lüthy R, Moelling K (2001) Phase I Clinical Trial with HIV-1 gp160 Plasmid Vaccine in HIV-1-infected Asymptomatic Subjects. *Eur J Clin Microbiol Infect Dis* 20:800-3.
  87. Rossi M, Flepp M, Telenti A, Schiffer V, Egloff N, Bucher H, Vernazza P, Bernasconi E, Weber R, Rickenbach M, Furrer H (2001) Disseminated *M. avium* complex infection in the Swiss HIV cohort study: Declining incidence, improved prognosis and discontinuation of maintenance therapy. *Swiss Medical Weekly* 131: 471-7.
  88. Wolf K\*, Tsakiris DA\* (\*contributed equally to this work), Weber R, Erb P, Battegay M (2002) Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. *J Infect Dis* 185:456-62.
  89. Opravil M, Hirschel B, Lazzarin A, Furrer HJ, Chave JP, Yerly S, Bisset LR, Fischer M, Vernazza P, Bernasconi E, Battegay M, Ledergerber B, Günthard H, Howe C, Weber R, Perrin L (2002) A Randomized Trial of Simplified Maintenance Therapy with Abacavir, Lamivudine, and Zidovudine in Human Immunodeficiency Virus Infection. *J Infect Dis* 185:1251-60.
  90. Fischer M, Wong JK, Russenberger D, Joos B, Opravil M, Hirschel B, Kuster H, Trkola A, Weber R, Günthard HF (2002) Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts. *Antivir Ther* 7:91-103.

91. Loré K, Sönnnerborg A, Broström C, Goh LE, Perrin L, McDade H, Stellbrink HJ, Gazzard B, Weber R, Napolitano LA, Kooyk Y, Andersson J (2002) Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection. *AIDS* 16:1-10.
92. Kronenberg A, Schupbach R, Schuknecht B, Bossart W, Weber R, Gilden DH, Speck RF (2002) Multifocal vasculopathy due to varicella-zoster virus (VZV): Serial analysis of VZV DNA and intrathecal synthesis of VZV antibody in cerebrospinal fluid. *Clin Infect Dis* 35:330-33.
93. Opravil M, Ledergerber B, Furrer HJ, Hirschel B, Imhof A, Gallant S, Wagels T, Bernasconi E, Meienberg F, Rickenbach M, Weber R (2002) Clinical Efficacy of Early Initiation of HAART in Patients with Asymptomatic HIV Infection and CD4 Counts >350/mm<sup>3</sup>. *AIDS* 16: 1371-81.
94. Oxenius A, McLean AR, Fischer M, Price DA, Dawson SJ, Hafner R, Schneider C, Joller H, Hirschel B, Phillips RE, Weber R, Günthard HF (2002) Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy. *J Virol* 76:10169-76.
95. Oxenius A, Price DA, Günthard HF, Dawson SJ, Perrin L, Fagard C, Fischer M, Weber R, Hirschel B, McLean A, Phillips RE (2002) Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. *Proc Nat Acad Sci* 99:13747-52.
96. Fagard C, Oxenius A, Günthard H, Garcia F, Mestre G, Le Braz M, Battegay M, Furrer HJ, Vernazza P, Bernasconi E, Telenti A, Weber R, Leduc D, Yerly S, Price D, Dawson SJ, Klimkait T, Perneger TV, McLean A, Clotet B, Gatell GM, Perrin L, Plana M, Phillips R, Hirschel B (2003) A prospective trial of structured treatment interruptions in HIV infection. *Arch Intern Med* 163:1220-6.
97. Bernasconi E, Boubaker K, Junghans C, Flepp M, Furrer HJ, Haensel A, Hirschel B, Boggian K, Chave JP, Opravil M, Weber R, Rickenbach M, Telenti A (2002) Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. *JAIDS-J Acq Imm Def* 31:50-5.
98. Bucher HC, Bichsel M, Taffé P, Furrer HJ, Telenti A, Hirschel B, Weber R, Bernasconi E, Vernazza P, Minder C, Battegay M (2002) Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naïve HIV-infected patients. The Swiss HIV Cohort Study. *HIV Medicine* 3:247-53.
99. Fischer M, Hafner R, Schneider C, Trkola A, Joos B, Joller H, Hirschel B, Weber R, Günthard HF (2003) HIV-plasma RNA rebounds within days during structured treatment interruptions. *AIDS* 17:195-9.
100. Friis-Møller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Calvo G, Law M, El-Sadr W, De Wit S, Sabin CA, Philips AN, Lundgren JD (2003) Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. *AIDS* 17:1179-93.
101. Law M, Friis-Møller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Calvo G, El-Sadr W, De Wit S, Sabin CA, Philips AN, Lundgren JD (2003) Modelling the three year risk of myocardial infarction among participants in the D.A.D. study. *HIV Medicine* 4:1-10.
102. Fischer M, Trkola A, Joos B, Hafner R, Joller H, Muesing MA, Kaufman DR, Berli E, Hirschel B, Weber R, Günthard HF (2003) Shifts in cell associated HIV-1 RNA but not in episomal HIV-1 DNA correlate with new cycles of HIV-1 infection in vivo. *Antivir Ther* 8:97-104.
103. Baumann D, Pusterla N, Péter O, Grimm F, Fournier PE, Schär G, Bossart G, Lutz H, Weber R (2003) Fieber nach Zeckenstich: Klinik und Diagnostik von akuten Zeckenstich-assoziierten Infektionskrankheiten in der Nordostschweiz. *Deut Med Wochenschr* 128:1042-47.
104. Page J\*, Weber R\* (\*contributed equally), Somaini B, Nöstlinger C, Donath K, Jaccard R (2003) Quality of generalist versus speciality care for people with HIV on antiretroviral treatment: A prospective cohort study. *HIV Medicine* 4:276-86.
105. Taillard C, Greub G, Weber R, Pfyffer GE, Bodmer T, Zimmerli S, Frei R, Bassetti S, Rohner P, Piffaretti JC, Bernasconi E, Bille J, Telenti A, Prod'hom G (2003) Clinical implications of *Mycobacterium kansasii* species heterogeneity: Swiss National Survey. *J Clin Microbiol* 41:1240-44.

106. Wolf K, Young J, Rickenbach M, Vernazza P, Flepp M, Furrer H, Bernasconi E, Hirschel B, Telenti A, Weber R, Bucher HC (2003) Prevalence of unsafe sexual behavior among HIV-infected individuals: The Swiss HIV Cohort Study. *JAIDS-J Acq Imm Def* 33:494-99.
107. Nöstlinger C, Page J, Jaccard R, Somaini B, Weber R (2003) Structures of co-operation between an HIV-outpatient clinic and private care physicians. *Das Gesundheitswesen* 65:90-95.
108. Metzner KJ, Bonhoeffer S, Fischer M, Karanickolas R, Allers K, Joos B, Weber R, Hirschel B, Kostrikis LG, Günthard HF (2003) Emergence of minor populations of HIV-1 bearing the M184V and L90M mutations in subjects undergoing structured treatment interruptions. *J Infect Dis* 188:1433-43.
109. Haupts S, Ledergerber B, Böni J, Schüpbach J, Kronenberg A, Opravil M, Flepp M, Speck RF, Grube C, Rentsch K, Weber R#, Günthard HF#, (#contributed equally) (2003) Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. *Antivir Ther* 8:443-54.
110. Trkola A, Kuster H, Leemann C, Ruprecht C, Joos B, Telenti A, Hirschel B, Weber R, Bonhoeffer S, Günthard HF (2003) Human Immunodeficiency Virus Type 1 Fitness Is a Determining Factor in Viral Rebound and Set Point in Chronic Infection. *J Virol* 77:13146-55.
111. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group (2003) Combination antiretroviral therapy and the risk of myocardial infarction. *N Engl J Med* 349:1993-2003.
112. Fischer M, Joos B, Wong JK, Ott P, Opravil M, Hirschel B, Weber R, Günthard HF (2004) Attenuated and Nonproductive Viral Transcription in Lymphatic Tissue of Human Immunodeficiency Virus Type 1 Infected Patients on Potent Antiretroviral Therapy. *J Infect Dis* 189:273-85.
113. Oxenius A, Price DA, Hersberger M, Telenti A, Schlaepfer E, Fischer M, Weber R, Weber M, Kundig TM, Böni J, Joller H, Phillips RE, Flepp M, Opravil M, Speck RF (2004) HIV-specific cellular immune response is correlated with disease progression as defined by the decline of CD4+ T cells in relation to HIV RNA. *J Infect Dis* 189:1199-208.
114. Weber R, Christen L, Christen S, Tschopp S, Znoj H, Schneider C, Schmitt J, Opravil M, Günthard HF, Ledergerber B (2004) Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy: prospective randomised trial. *Antivir Ther* 9:85-95.
115. Kaufmann GR, Khanna N, Weber R, Perrin L, Furrer HJ, Cavassini M, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Hirschel B, Battegay M (2004) Multiple changes of potent antiretroviral therapy and long-term virologic response in HIV-1 infection. *Antivir Ther* 9:263-274.
116. The PLATO Collaboration (Writing Committee: Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, Mussini C, Wit F, d'Arminio Monforte A, Weber R, Fusco G, Staszewski S, Law M, Hogg R, Lampe F, Gill MJ, Castelli F, Phillips AN) (2004). Predictors of CD4 count trend and Mortality among HIV-1 - Infected Persons with Virologic Failure to all Three Antiretroviral Drug Classes. *Lancet* 2004;364:51-62.
117. Gläser C, Grimm F, Mathis A, Weber R, Nadal D, Deplazes P (2004) Detection and molecular characterization of *Cryptosporidium* spp. Isolated from diarrheic children in Switzerland. *Pediatric Infect Dis J* 23(4):359-61.
118. Sendi P, Schellenberg F, Ungsedhapand C, Kaufmann GR, Bucher HC, Weber R, Battegay M, and the Swiss HIV Cohort Study (2004) Productivity costs and determinants of productivity in HIV-infected patients. *Clin Ther* 26:791-800.
119. Hansjee N\*, Kaufmann GR\* [contributed equally], Strub C, Weber R, Battegay M, Erb P, and the Swiss HIV Cohort Study (2004) Persistent apoptosis in HIV-1 infected individuals receiving potent antiretroviral therapy is associated with poor recovery of CD4 T-lymphocytes. *JAIDS-J Acq Imm Def* 36:671-677.
120. Hasse B, Ledergerber B, Egger M, Flepp M, Bachmann S M, Bernasconi E, Egger M, Guyot S, Hirschel B, Weber R, and Günthard HF, and the Swiss HIV Cohort Study (2004) Antiretroviral treatment and osteonecrosis in patients of the Swiss HIV Cohort Study: A nested case-control study. *AIDS Res Hum Retrov* 2004;20:909-915.
121. Trkola A, Kuster H, Leemann C, Oxenius A, Fagard C, Telenti A, Furrer HJ, Battegay M, Vernazza P, Bernasconi E, Weber R, Hirschel B, Bonhoeffer S, Günthard H, and the Swiss HIV cohort study (2004) Humoral immunity to HIV-1: Kinetics of antibody responses in chronic infection reflect capacity of immune system to improve viral set point. *Blood* 2004;104:1784-1792.

122. D'Arminio Monforte A, Sabin C, Reiss P, Weber R, Kirk O, El-Sadr W, De Witt S, Mateu S, Petoumenos K, Dabis F, Pradier C, Morfeldt L, Phillips AN, Lundgren JD, Friis-Møller N (2004) Cardio- and Cerebrovascular Events in HIV-infected Persons. Results from the D:A:D Study. *AIDS* 18:1811-1817.
123. Keiser O, Taffé P, Zwahlen M, Battegay M, Bernasconi E, Weber R, Rickenbach M, and the Swiss HIV Cohort Study (2004) All Cause Mortality in the Swiss HIV Cohort Study from 1990 to 2001 in Comparison to the Swiss Population. *AIDS* 18:1835-1843.
124. Glass T, Young J, Vernazza PL, Rickenbach M, Weber R, Cavassini M, Hirschel B, Battegay M, Bucher HC, and the Swiss HIV Cohort (2004) Is unsafe sexual behaviour increasing among HIV-infected individuals? *AIDS* 2004, 18:1707-1714.
125. Fischer M, Joos B, Hirschel B, Bleiber G, Weber R, Günthard HF, and the Swiss HIV Cohort Study (2004) Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding *nef*. *J Infect Dis* 190:1979-88.
126. Huber M, Weber R, Oppliger R, Vernazza P, Schmid P, Schönbucher P, Bertisch B, Meili D, Renner EL (2005) Interferon-alpha2a plus Ribavirin 1000/1200 mg versus Interferon-alpha2a plus Ribavirin 600 mg for Chronic Hepatitis C Infection in Patients on Opiate Maintenance Treatment: An Open-label Randomized Multicenter Trial. *Infection* 33:25-29.
127. Lowy A, Page J, Jaccard R, Ledergerber B, Somaini B, Weber R, Szucs T (2005) Costs of treatment of Swiss patients with HIV on antiretroviral therapy in hospital-based and general practice-based care: a prospective cohort study. *AIDS Care* 17:698-710.
128. Tarr PE, Taffé P, Bleiber G, Furrer HJ, Rotger M, Martinez R, Hirschel B, Battegay M, Weber R, Vernazza P, Darioli R, Rickenbach M, Ledergerber B, Telenti A, and the Swiss HIV Cohort Study (2005) Modeling the influence of APOC3, APOE and TNF polymorphisms on the risk of antiretroviral therapy-associated dyslipidemia. *J Infect Dis* 191:1419-26.
129. Rusert P, Kuster H, Joos B, Misselwitz B, Gujer C, Leemann C, Fischer M, Stiegler G, Katinger H, Olson WC, Weber R, Aceto L, Günthard HF, Trkola A (2005) Virus isolates during acute and chronic HIV infection show distinct patterns of sensitivity to entry inhibitors. *J Virol* 79:8454-8469.
130. Rauch A, Rickenbach M, Weber R, Hirschel B, Tarr P, Bucher H, Vernazza P, Bernasconi E, Zinkernagel AS, Evison J, Furrer HJ and the Swiss HIV Cohort Study (2005) Unsafe sex and increasing incidence of Hepatitis C Virus infection among HIV infected men who have sex with men: The Swiss HIV Cohort Study. *Clin Infect Dis* 41:395-402.
131. Joos B, Trkola A, Fischer M, Kuster H, Rusert P, Leemann C, Böni J, Oxenius A, Price DA, Phillips RE, Wong JK, Hirschel B, Weber R, Günthard HF and the Swiss HIV Cohort Study (2005) Low Human Immunodeficiency Virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions. *J Virol* 79:9026-37.
132. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, Weber R, Stiegler B, Vcelar B, Katinger H, Aceto L, Günthard HF (2005) Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. *Nat Med* 79:8454-69.
133. Sterne JAC, Hernán MA, Ledergerber B, Tilling K, Weber R, Sendi P, Rickenbach M, Robins J, Egger M, and the Swiss HIV Cohort Study (2005) Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: the Swiss HIV Cohort Study. *The Lancet* 366:378-384.
134. Imhof A, Ledergerber A, Günthard HF, Haupts S, Weber R, and the Swiss HIV Cohort Study (2005) Risk-Factors for and Outcome of Hyperlactatemia in HIV-infected Persons: Is there a Need for Routine Lactate Monitoring? *Clin Infect Dis* 41:721-8
135. Young J, Weber R, Rickenbach M, Furrer HJ, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC; and the Swiss HIV Cohort Study (2005) Lipid profiles for antiretroviral-naïve patients starting PI- and NNRTI- based therapy in the Swiss HIV Cohort Study. *Antivir Ther* 10:585-591.
136. Wunder D, Bersinger NA, Fux C, Weber R, Bernasconi F, Cavassini M, Bucher HC, Schiffer V, Schmid P, Furrer HJ, and the Swiss HIV Cohort Study (2005) Plasma leptin levels in men are not related to development of lipoatrophy during antiretroviral therapy. *AIDS* 19:1837-42.

137. Aceto L, Karrer U, Grube C, Oberholzer R, Hasse B, Presterl E, Böni J, Kuster H, Trkola A, Weber R, Günthard HF (2005) Die akute HIV-1-Infektion in Zürich: 2002–2004 [Primary HIV-1 Infection in Zurich: 2002–2004] *Schweiz Rundsch Med Prax* 94: 1199–1205.
138. Karrer U, Ledergerber B, Furrer HJ, Elzi L, Gayet-Ageron A, Cavassini M, Schmid P, Russotti M, Weber R, Speck RF, and the Swiss HIV Cohort Study (2005) Dose dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. *AIDS* 19:1987–1994.
139. Young J, Rickenbach M, Weber R, Furrer HJ, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC; and the Swiss HIV Cohort Study (2005) Body fat changes among antiretroviral-naïve patients on PI and NNRTI-based HAART in the Swiss HIV Cohort Study. *Antivir Ther* 10:73-81.
140. Glass TR, De Geest S, Weber R, Vernazza PL, Rickenbach M, Furrer HJ, Bernasconi E, Cavassini M, Hirschel B, Battegay M, Bucher HC, and the Swiss HIV Cohort Study (2006) Correlates of self reported non-adherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. *JAIDS-J Acq Imm Def* 41:385-392.
141. Zinkernagel AS, von Wyl V, Ledergerber B, Rickenbach M, Furrer HJ, Battegay M, Hirschel B, Tarr PE, Opravil M, Bernasconi E, Schmid P, Weber R, and the Swiss HIV Cohort Study (2006) Eligibility for and Outcome of Hepatitis C Treatment of HIV Co-infected Persons in Clinical Practice: The Swiss HIV Cohort Study. *Antivir Ther* 11:131-142.
142. Hürlimann D, Chenevard R, Ruschitzka F, Flepp M, Enseleit F, Béchir M, Kobza R, Muntwyler J, Ledergerber B, Lüscher TF, Noll G, Weber R (2006) Effects of HMG-CoA Reductase Inhibition on Endothelial Function and Lipid Profile in HIV-infected Persons on Protease Inhibitor-containing Antiretroviral Combination Therapy: A Randomized Double-Blind Cross-Over Trial. *HEART* 92:110-112.
143. Law MG, Friis-Møller N, El-Sadr WM, Weber R, Reiss P, D'Arminio Monforte A, Thiébaud R, Morfeldt L, De Wit S, Pradier C, Calvo G, Kirk O, Sabin CA, Phillips AN, Lundgren JD, for the D:A:D Study Group (2006) The Use of the Framingham Equation to Predict Myocardial Infarctions in HIV-infected Patients: Comparison with Observed Events in the D:A:D Study. *HIV Med* 7:218-230.
144. Müller NJ, Furrer HJ, Kaiser L, Hirschel B, Cavassini M, Fellay J, Chave JP, Wüthrich RP, Weber M, Müllhaupt B, Candinas D, Reichen D, Giostra E, Mentha G, Halkic N, Hirsch HH, Weber R, and the Swiss HIV Cohort Study (2006) HIV and solid organ transplantation: The Swiss experience. *Swiss Medical Weekly* 136:194-196.
145. Glass TR, Ungsedhapand C, Wolbers M, Weber R, Vernazza PL, Rickenbach M, Furrer H, Bernasconi E, Cavassini M, Hirschel B, Battegay M, Bucher HC, and the Swiss HIV Cohort Study (2006) Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. *HIV Medicine* 7:404-410.
146. Widmer IC, Erb P, Grob H, Itin P, Baumann M, Stalder A, Weber R, Cathomas G (2006) Human Herpes Virus 8 oral shedding in HIV-infected Men with and without Kaposi's Sarcoma. *JAIDS-J Acq Imm Def* 42:420-5.
147. Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, de Wit S, Åkerlund B, Calvo G, d'Arminio Monforte A, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD (2006) Liver-related Deaths among Persons Infected with the Human Immunodeficiency Virus: The D:A:D Study. *Arch Intern Med* 166:1632-1641.
148. Funk GA, Oxenius A, Fischer M, Opravil M, Joos B, Flepp M, Weber R, Günthard HF, Bonhoeffer S (2006) HIV replication elicits little cytopathicity in vivo: Analysis of surrogate markers for virus production, cytotoxic T cell response and infected cell death. *J Med Virol* 78:1141-1146.
149. Kaiser Ph, Niederöst B, Joos B, Ledergerber B, Opravil M, Weber R, Günthard HF, Fischer M (2006) Equal Amounts of Intracellular and Virion-enclosed Hepatitis C Virus RNA in Peripheral Blood Mononuclear Cells in Vivo. *J Infect Dis* 194:1713-1723.
150. Gaudieri S, Rauch A, Park LP, Freitas E, Herrmann S, Jeffrey G, Cheng W, Pfafferott K, Naidoo K, Chapman R, Battegay M, Weber R, Telenti A, Furrer HJ, James I, Lucas M, Mallal SA, and the Swiss HIV Cohort Study (2006) Evidence of viral adaptation to HLA Class I-restricted immune pressure in chronic Hepatitis C virus infection. *J Virol* 80;11094-11104.
151. Rabodnirina M, Nahimana A, Weber R, Francioli P, Bille J, Hauser PM (2006) Geographical Variation in the Prevalence of Pneumocystis jirovecii Dihydropteroate Synthase Mutations Within Western Europe. *J Eukaryot Microbiol* 53:S112–S113.

152. Huber M, Fischer M, Misselwitz B, Manrique A, Kuster H, Niederöst B, Weber R, von Wyl V, Günthard HF, Trkola A (2006) Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 Infection. *PLOS Medicine* 11:(e441):2078-2093.
153. Elzi L, Schlegel M, Weber R, Hirschel B, Cavassini M, Schmid P, Bernasconi E, Rickenbach M, Furrer HJ, and the Swiss HIV Cohort Study (2007) Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment and antiretroviral therapy in an area of low tuberculosis transmission. *Clin Infect Dis* 44:94-102
154. Rauch A, Laird R, McKinnon E, Telenti A, Furrer HJ, Weber R, Smillie D, Gaudieri S; and the Swiss HIV Cohort (2007). Influence of inhibitory KIRs and their HLA-C ligands on resolving HCV infection. *Tissue Antigens* 69 (Suppl 1):237-40 (*peer-reviewed original article*).
155. Mocroft A, Staszewski S, Weber R, Gatell J, Rockstroh J, Gasirowski J, Panos G, d'Arminio Monforte A, Rakhmanova A, Phillips AN, Lundgren JD, on behalf of the EuroSIDA study group (2007) Risk of discontinuation of nevirapine due to toxicities in antiretroviral naive and experienced HIV-infected patients with high and low CD4 counts. *Antiviral Therapy* 12:325-33.
156. Fenner L, Weber R, Steffen R, Schlagenhauf P (2007) Spectrum of travel associated infectious disease in relation to purpose of travel. *Emerg Infect Dis* [serial on the Internet]. 2007 Feb [date cited]. Available from <http://www.cdc.gov/EID/content/13/2/217.htm>
157. Sendi P, Brouwer W, Bucher H, Weber R, Battegay M (2007) When time is more than money: the allocation of time between work and leisure in HIV-infected patients. *Social Science & Medicine* 64:2355-61.
158. Friis-Møller N, Reiss P, Sabin CA, Weber R, D'Arminio Monforte A, El-Sadr W, Thiébaud R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD, and the DAD study group (2007) Risk of Myocardial Infarction in Association with Different Classes of Antiretroviral Drugs. *New Engl J Med* 356:1723-35.
159. Glass TR, Weber R, Vernazza PL, Rickenbach M, Furrer HJ, Bernasconi E, Cavassini M, Hirschel B, Battegay M, Bucher HC, and the Swiss HIV Cohort Study (2007) Ecological study of the predictors of successful management of dyslipidemia in HIV-infected patients on ART: the Swiss HIV Cohort Study. *HIV Clinical Trials* 8:77-85.
160. Huttner AC, Kaufmann GR, Battegay M, Weber R, Opravil M, and the Swiss HIV Cohort Study (2007) Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs the CD4 cell recovery but not the clinical efficacy. *AIDS* 21:939-946.
161. Arnedo M, Taffé P, Sahli R, Furrer HJ, Hirschel B, Elzi L, Weber R, Vernazza P, Bernasconi E, Darioli R, Bergmann S, Beckmann JS, Telenti A, Tarr PE (2007) Contribution of 20 SNPs of 13 genes to dyslipidemia associated with antiretroviral therapy. *Pharmacogenetics and Genomics* 17:755-764
162. Joos B, Fischer M, Schweizer A, Kuster H, Böni J, Wong JK, Weber R, Trkola A, Günthard HF (2007) Positive in vivo selection of HIV-1 envelope gp120 occurs at surface exposed regions. *J Infect Dis* 196:313-20.
163. Manrique A, Rusert P, Joos B, Fischer M, Kuster H, Leemann C, Niederöst B, Weber R, Stiegler G, Katinger H, Günthard HF, Trkola A (2007). In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. *J Virol* 81:8793-808.
164. Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, Cavassini M, Bernasconi E, Schmid P, Egger M, Weber R and the Swiss HIV Cohort Study (2007) Factors Associated with the Incidence of Diabetes mellitus Type 2 in HIV-infected Participants of the Swiss HIV Cohort Study. *Clin Infect Dis* 45:111-9.
165. Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarne D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S, for the QUEST Study Group (2007) Predictors of Virological Outcome and Safety in Primary HIV-1 infected Patients Initiated on Quadruple ART (QUEST GW PROB3005). *Clin Infect Dis* 45:381-9.
166. Kaiser Ph, Joos B, Niederöst B, Weber R, Günthard HF, Fischer M, and The Swiss HIV Cohort Study (2007) Productive Human Immunodeficiency Virus 1 Infection in peripheral Blood Predominantly Takes Place in CD4/CD8 double negative T Lymphocytes. *J Virol* 81:9693-706.
167. Arenas-Pinto A, Copas A, Weller I, Grant A, Dunn D, Bhaskaran K, Carr A, Reiss P, Edwards S, Westring Worm S, Overton T, Martinez E, Hoy J, Cahn P, Weber R (2007) Risk factors for lactic

- acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. *AIDS* 21:2455-64.
168. Berger S, Schad T, von Wyl V, Ehler U, Zellweger C, Furrer HJ, Regli D, Vernazza P, Ledergerber B, Battegay M, Weber R\*, Gaab J\* (\*contributed equally) (2008) Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. *AIDS* 22:767-775.
  169. Trkola A, Kuster H, Rusert P, von Wyl V, Leemann C, Weber R, Stiegler G, Katinger H, Joos B, Günthard HF (2008) In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. *J Virol* 82:1591-9.
  170. Sabin CA, d'Arminio Monforte A, Friis-Møller N, Weber R, El-Sadr WM, Reiss P, Kirk O, Mercie P, Law MG, De Wit S, Pradier C, Phillips AN, Lundgren JD (2008) Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs among HIV-infected individuals and impact on myocardial infarction. *Clin Infect Dis* 46:1101-10.
  171. Garbino J, Inoubli S, Mossdorf E, Weber R, Tamm M, Soccal P, Aubert JD, Tapparel C, Kaiser L, and the Swiss HIV Cohort Study (2008) Respiratory viruses in HIV-infected patients with suspected respiratory opportunistic infection. *AIDS* 22:701-5.
  172. Glass TR, De Geest S, Hirschel B, Battegay M, Furrer HJ, Cavassini M, Vernazza PL, Bernasconi E, Rickenbach M, Weber R, Bucher HC, and the Swiss HIV Cohort Study (2008) Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. *Antivir Ther* 13:77-85.
  173. Vo TTN, Ledergerber B, Keiser O, Hirschel B, Furrer HJ, Battegay M, Cavassini M, Bernasconi E, Vernazza P, Weber R, and the Swiss HIV Cohort Study (2008) Durability and Outcome of Initial Antiretroviral Treatments from 2000 to 2005 in the Swiss HIV Cohort Study. *J Infect Dis* 197:1685-94.
  174. Rauch A, Gaudieri S, Evison J, Nolan D, Cavassini M, Weber R, James J, Furrer HJ and the Swiss HIV Cohort Study (2008) Low current and nadir CD4 T-cell counts are associated with higher Hepatitis C RNA levels in the Swiss HIV Cohort Study (SHCS). *Antiviral Ther* 13:455-60.
  175. Huber M, von Wyl V, Ammann CG, Kuster H, Stiegler G, Katinger H, Weber R, Fischer M, Stoiber H, Günthard HF, Trkola A (2008) Potent HIV-Neutralizing and Complement Lysis Activity of Antibodies Are Not Obligatorily Linked. *J Virol* 82:3834-42.
  176. de Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, El-Sadr W, d'Arminio Monforte A, Fontas E, Law MG, Friis-Møller N, Lundgren JD, for the DAD study group (2008) Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the D:A:D study. *Diabetes Care* 31:1224-9.
  177. Sabin CA, Worm S, Weber R, Reiss P, El-Sadr W, Dabis F, DeWit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD, for the D:A:D study group (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D stud: a multi-cohort collaboration. *Lancet* 371:1417-26.
  178. Kuster SP, Ruef C, Ledergerber B, Hintermann A, Deplazes C, Neuber L, Weber R (2008) Quantitative Antibiotic Use in Hospitals: Comparison of Measurements, Literature Review and Recommendations for a Standard of Reporting. *Infection*. 2008;36:549-59.
  179. Wolbers M, Bucher HC, Furrer H, Rickenbach M, Cavassini M, Weber R, Schmid P, Bernasconi E, Hirschel B, Battegay M; the Swiss HIV Cohort Study (2008) Delayed diagnosis of HIV infection and late initiation. *HIV Med* 9:397-405.
  180. Kuster SP, Ruef C, Bollinger AK, Ledergerber B, Hintermann A, Deplazes C, Neuber L, Weber R (2008) Correlation between Case Mix Index and Antibiotic Use in Hospitals. *J Antimicrob Chemother* 62:837-842.
  181. Khanna N, Opravil M, Furrer HJ, Cavassini M, Vernazza P, Bernasconi E, Weber R, Hirschel B, Battegay M, Kaufmann GR, and the Swiss HIV Cohort Study (2008) CD4 T-cell count recovery in HIV-1 infected patients is independent of the class of antiretroviral therapy. *Clin Infect Dis* 47:1093-1101.
  182. Lundgren JD, Neuhaus J, Babiker A, Cooper D, Duprez D, El-Sadr W, Emery S, Gordin F, Kowalska J, Phillips A, Prineas RJ, Reiss P, Sabin C, Tracy R, Weber R, Grund B, Neaton JD (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the SMART study. *AIDS* 22:F17-F24.

183. d'Arminio Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD (2008) HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies: the D:A:D Study. *AIDS* 22:2143-53.
184. Kuster S, Rued C, Zbinden R, Gottschalk J, Ledergerber B, Neuber L, Weber R (2008) Stratification of Cumulative Antibigrams in Hospitals for Hospital Unit, Specimen Type, Isolate Sequence and Duration of Hospital Stay. *J Antimicrob Chemother* 62:1451-61.
185. Joos B, Fischer M, Kuster H, Wong JK, Böni J, Hirschel B, Weber R, Trkola A, Günthard HF, and the Swiss HIV Cohort Study (2008) Rebounding HIV upon treatment interruption implies reactivation of latently infected cells rather than origin from low level replication. *Proc Nat Acad Sci (PNAS)* 105:16725-30.
186. Fischer M, Joos B, Niederöst B, Kaiser Ph, Hafner R, von Wyl V, Ackermann M, Weber R, Günthard HF (2008) Biphasic Decay Kinetics Suggest Progressive Slowing in Turnover of Latently HIV-1 Infected Cells During Antiretroviral Therapy. *Retrovirology*. 5(1):107. doi:10.1186/1742-4690-5-107
187. Bellini C, Keiser O, Chave JP, Evison JM, Fehr J, Kaiser L, Weber R, Vernazza P, Bernasconi E, Telenti A, Cavassini M, and the Swiss HIV Cohort Study (2009) Liver enzyme elevation after lamivudine withdrawal in HIV/hepatitis B virus co-infected patients: The Swiss HIV Cohort Study. *HIV Med* 10(1):12-8.
188. Worm SW, De Wit S, Weber R, Sabin CA, Reiss P, El-Sadr W, D'Arminio Monforte A, Kirk O, Fontas E, Dabis F, Law MG, Lundgren JD, Friis-Møller N (2009) Diabetes mellitus, pre-existing coronary heart disease and the risk of subsequent CHD events in HIV-infected patients: The D:A:D Study. *Circulation* 119:805-11.
189. Conen A, Fehr J, Glass TR, Furrer HJ, Weber R, Vernazza P, Hirschel B, Cavassini M, Bernasconi E, Bucher HC, Battegay M, and The Swiss HIV Cohort Study (2009) Self-reported alcohol consumption and association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. *Antivir Ther* 14:349-357.
190. Weber R\*, Huber M\* [\*contributed equally], Rickenbach M, Furrer HJ, Elzi L, Hirschel B, Cavassini M, Bernasconi E, Schmid P, Ledergerber B, and the Swiss HIV Cohort Study (2009) Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment program: The Swiss HIV Cohort Study. *HIV Med* 10, 407–416.
191. Flammer AJ, Vo NTT, Ledergerber B, Hermann F, Gämperli A, Huttner A, Evison J, Baumgartner I, Cavassini M, Hayoz D, Quitzau K, Hersberger M, Sudano I, Ruschitzka f, Lüscher TF, Noll G, Weber R (2009) Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: Randomized controlled trial. *Heart* 95:385-390.
192. Joos B, Rieder P, Fischer M, Kuster H, Rusert P, Trkola A, Pillai SK, Wong JK, Weber R, Günthard HF (2010) Association between Specific HIV-1 Env Traits and Virologic Control in vivo. *Infection, Genetics and Evolution* 10:365-72.
193. Kovari H, Ledergerber B, Peter U, Flepp M, Jost J, Schmid P, Calmy A, Mueller NJ, Müllhaupt B, Weber R, and the Swiss HIV Cohort Study (2009) Association of noncirrhotic portal hypertension (NCPH) in HIV-infected persons and antiretroviral therapy with didanosine (DDI). A nested case control study. *Clin Infect Dis* 2009; 49:626–35.
194. Elzi L, Kaufmann G, Weber R, Fux CA, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Battegay M, and the Swiss HIV Cohort Study (2009) Discontinuation of Enfuvirtide in Heavily Pretreated HIV-Infected Individuals. *HIV Clin Trials* 2009;10(4):207–214.
195. Rotger M, Bayard C, Taffé P, Martinez R, Cavassini M, Bernasconi E, Battegay M, Hirschel B, Furrer HJ, Witteck A, Weber R, Ledergerber B, Telenti A, Tarr PE, and the Swiss HIV Cohort Study (2009) Contribution of genome-wide significant single nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals - a longitudinal study. *Circ Cardiovasc Genet* 2:621-628.
196. Ballif M, Ledergerber B, Battegay M, Cavassini M, Bernasconi E, Schmid P, Hirschel B, Furrer HJ, Rickenbach M, Opravil M, Weber R, and the Swiss HIV Cohort Study (2009) Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007: The Swiss HIV Cohort Study. *PLoS ONE* 4: e8275.



197. Gianella S, Haeberli L, Joos B, Ledergerber B, Wüthrich RP, Weber R, Kuster H, Hauser PM, Fehr T, Mueller NJ (2010) Molecular evidence of interhuman transmission in an outbreak of *Pneumocystis jirovecii* pneumonia among renal transplant recipients. *Transpl Infect Dis* 2010;12:1-10.
198. Ferry T, Hirschel B, Dang T, Meylan P, Delhumeau C, Rauch A, Weber R, Elzi L, Bernasconi E, Vernazza P, Calmy A, and the Swiss HIV Cohort Study (2010) Infrequent replication of parvovirus B19 and erythrovirus genotypes 2 and 3 among HIV-infected patients with chronic anemia. *Clin Infect Dis* 2010;50:115-8.
199. Bucher HC, Rickenbach M, Young J, Glass TR, Vallet Y, Bernasconi E, Cavassini M, Fux C, Schiffer V, Vernazza P, Weber R, Battegay M, and the Swiss HIV Cohort Study (2010) Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy. *Antivir Ther* 2010; 15: 31-40.
200. Opravil M, Klimkait T, Louvel S, Wolf E, Battegay M, Fux CA, Bernasconi E, Vogel M, Speck R, Weber R, and the Swiss HIV Cohort Study (2010) Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection. *JAIDS-J Acq Imm Def* 54:51-8.
201. Elzi L, Marzolini C, Furrer HJ, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Weber R, Battegay M, and the Swiss HIV Cohort Study (2010) Treatment Modification in HIV-Infected Individuals Starting Combination Antiretroviral Therapy Between 2005 and 2008. *Arch Intern Med* 170:57-65.
202. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Fontas E, Weller I, Phillips A, Lundgren J, for the D:A:D study group (2010) Risk of myocardial infarction in HIV patients exposed to specific individual antiretroviral drugs from the three major drug classes: the DAD study. *J Infect Dis* 201;318-330.
203. Kuster SP\*, Hasse B\*, Huebner V\* (\*contributed equally), Bansal V, Zbinden R, Ruef C, Ledergerber B, Weber R (2010) Risks Factors for Infections with Extended-Spectrum Beta-Lactamase Producing *Escherichia coli* and *Klebsiella pneumoniae* at a Tertiary Care University Hospital in Switzerland 2005-2007. *Infection* 2010;38:33-40.
204. Kovari H, Ledergerber B, Battegay M, Rauch A, Hirschel B, Foguena AK, Vernazza P, Bernasconi E, Mueller NJ, Weber R, and the Swiss HIV Cohort Study (2010) Incidence and Risk Factors for Chronic Elevation of Alanine Aminotransferase in HIV-Infected Persons without Hepatitis B or C Virus Co-infections. *Clin Infect Dis* 2010; 50:502-11.
205. Schlagenhauf P, Chen LH, Wilson ME, Freedman DO, Tcheng D, Schwartz E, Pandey P, Weber R, Nadal D, Berger C, von Sonnenburg F, Keystone J, Leder K for the GeoSentinel Surveillance Network (2010) Gender Differences in Travel-Associated Disease. *Clin Infect Dis* 50:826-32.
206. Metzner KJ, Rauch P, von Wyl V, Leemann C, Grube C, Kuster H, Böni J, Weber R, Günthard HF (2010) Efficient suppression of minority quasispecies of drug-resistant viruses present at primary HIV-1 infection by RTV-boosted protease inhibitor containing ART. *J Infect Dis* 210:1063-71.
207. Znoj HJ, Messerli-Burgy N, Tschopp S, Weber R, Christen L, Christen S, Grawe K (2010) Psychotherapeutic process of cognitive-behavioral intervention in HIV-infected persons: Results from a controlled, randomized prospective clinical trial. *Psychother Res.* 20:203-213.
208. Kouyos RD, von Wyl V, Yerly S, Böni J, Taffé P, Shah C, Bürgisser P, Klimkait T, Weber R, Hirschel B, Cavassini M, Furrer HJ, Battegay M, Vernazza PL, Bernasconi E, Rickenbach M, Ledergerber B, Bonhoeffer S, Günthard HF, and the Swiss HIV Cohort Study (2010) Molecular epidemiology reveals long-term changes in HIV-1 subtype B transmission in Switzerland. *J Infect Dis* 201;1488-97.
209. Rieder P, Joos B, von Wyl V, Kuster H, Grube C, Leemann C, Böni J, Yely S, Klimkait T, Bürgisser P, Weber R, Fischer M, Günthard HF, and the Swiss HIV Cohort Study (2010) HIV-1 transmission after cessation of early antiretroviral therapy among MSM. *AIDS* 24:1177-83.
210. Nicoletti J, Kuster SP, Sulser T, Zbinden R, Ruef C, Ledergerber B, Weber R (2010) Risk factors for urinary tract infections due to ciprofloxacin-resistant *Escherichia coli* in a tertiary care urology department in Switzerland. *Swiss Med Wkly* 140:w13059. doi: 10.4414/smw.2010.13059.
211. Fehr JS\*, Bloemberg GV\* (\*contributed equally), Ritter C, Hombach M, Lüscher TF, Weber R, Keller PM (2010) Septicemia due to a Tick-borne Bacterial Pathogen '*Candidatus Neoehrlichia mikurensis*.' *Emerging Infectious Diseases* 16:1127-9.

212. Hauser PM, Nahimana A, Taffe P, Weber R, Francioli P, Bille J, Rabodonirina M (2010) Interhuman transmission as a potential key parameter for geographical variation in the prevalence of *Pneumocystis jirovecii* dihydropteroate synthase mutations. *Clin Infect Dis* 51:e28-33.
213. Thurnheer MC, Weber R, Toutous-Trellu L, Cavassini M, Elzi L, Schmid P, Bernasconi E, Christen AB, Zwahlen M, Furrer HJ (2010) Occurrence, risk factors, diagnosis and treatment of syphilis in the prospective observational Swiss HIV Cohort Study. *AIDS*; 24:1907–1916.
214. Hasse B, Ledergerber B, Hirschel B, Vernazza P, Glass TR, Jeannin A, Evison JM, Elzi L, Cavassini M, Bernasconi E, Nicca D, Weber R, and the Swiss HIV Cohort Study (2010) Frequency and determinants of unprotected sex of HIV-infected persons: The Swiss HIV Cohort Study. *Clin Infect Dis* 51:1314-1322.
215. Schmid A\*, Gianella S\*, Von Wyl V, Metzner KJ, Scherrer A, Niederöst B, Althaus CF, Joos B, Weber R, Fischer M\*, Günthard HF\* (\*contributed equally) (2010) Profound Depletion of HIV-1 Transcription in Patients Initiating Antiretroviral Therapy during Acute Infection. *PLoS ONE* 5:e13310.
216. Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer HJ, Chave JP, Cavassini M, Bernasconi E, Calmy A, Vernazza P, Khoo S, Lederberger B, Back D, Battegay M, and the Swiss HIV Cohort Study (2010) Prevalence of co-medications and impact of potential drug-drug interactions in the Swiss HIV Cohort Study. *Antivir Ther* 15:413-423.
217. Rotger M, Gsponer T, Martinez R, Taffe P, Elzi L, Vernazza P, Cavassini M, Bernasconi E, Hirschel B, Furrer HJ, Weber R, Ledergerber B, Egger M, Telenti A, Tarr PE, and the Swiss HIV Cohort Study (2010) Impact of single nucleotide polymorphisms and of clinical risk factors on new-onset Diabetes mellitus in HIV-infected individuals. *Clin Infect Dis* 51:1090-8.
218. Smith CJ, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, d'Arminio Monforte A, Kirk O, Friis-Møller N, Phillips A, Reiss P, El Sadr W, Pradier C, Worm SW (2010) Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. *AIDS* 24:1537–1548.
219. Cusini A, Rampini SK, Bansal V, Ledergerber B, Kuster SP, Ruef C, Weber R (2010) Different patterns of inappropriate antimicrobial use in surgical and medical units at a tertiary care hospital in Switzerland: A qualitative prevalence survey *PLoS ONE* 5(11): e14011. doi:10.1371/journal.pone.0014011.
220. Weber R, Sabin C, Reiss P, De Wit S, Worm SW, Law M, Dabis F, D'Arminio Monforte A, Fontas E, El-Sadr W, Kirk O, Rickenbach M, Phillips A, Ledergerber B, Lundgren J, for the D:A:D Study Group (2010) Hepatitis B or C virus co-infections and risk of myocardial infarction in HIV-infected persons: The D:A:D Cohort Study. *Antivir Ther* 15:1077-86.
221. Friis-Møller N, Thiébaud R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG; DAD study group (2010) Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. *Eur J Cardiovasc Prev Rehabil* 17:491-501.
222. Ledergerber B, Cavassini M, Battegay M, Bernasconi E, Vernazza P, Hirschel B, Furrer HJ, Rickenbach M, Weber R, and the Swiss HIV Cohort Study (SHCS) (2011) Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study. *HIV Med* 12:279-88.
223. Petoumenos K, Worm S, Reiss P, De Wit S, D'Arminio Monforte A, Sabin C, Friis-Møller N, Weber R, Mercie P, Pradier C, El-Sadr W, Kirk O, Lundgren J, Law M, on behalf of the D:A:D Study Group (2011) Rates of cardiovascular disease following smoking cessation in patients with HIV infection: Results from the D:A:D Study. *HIV Med* 12:412-21.
224. Gianella S, von Wyl V, Fischer M, Niederoest B, Battegay M, Bernasconi E, Cavassini M, Rauch A, Hirschel B, Vernazza P, Weber R, Joos B, Günthard HF, and the Swiss HIV Cohort Study (SHCS) (2011) Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. *Antivir Ther* 16:535-45.
225. Kouyos RD, von Wyl V, Yerly S, Böni J, Rieder P, Joos B, Taffé P, I Shah C, Bürgisser P, Klimkait T, Weber R, Hirschel B, Cavassini M, Furrer HJ, Battegay M, Vernazza PL, Bernasconi E, Rickenbach M, Ledergerber B, Bonhoeffer S, Günthard HF, and the Swiss HIV Cohort Study (2011) Ambiguous nucleotide calls from population based sequencing of HIV-1 are a marker for viral diversity and the age of infection. *Clin Infect Dis* 52:532-9.
226. Kaufmann GR, Elzi L, Weber R, Furrer HJ, Giulieri S, Vernazza P, Bernasconi E, Hirschel B, Battegay M, and The Swiss HIV Cohort Study (2011) Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. *AIDS* 25:441–451.

227. Arenas-Pinto A, Grant A, Bhaskaran K, Copas A, Carr A, Worm SW, Martinez E, Reiss P, Dunn D, Weber R, Hoy J, Weller I, and the Lactic Acidosis International Study Group (2011) Risk factors for fatality in HIV-infected patients with dideoxynucleoside-induced severe hyperlactataemia or lactic acidosis. *Antivir Ther* 16(2):219-26.
228. Haas A, Graw F, Slack E, Rusert P, Bossart W, Ledergerber B, Weber R, Furrer HJ, Battegay M, Hirschel B, Vernazza P, Macpherson A, Günthard HF, Oxenius A, and the Swiss HIV Cohort Study (2011) Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. *Gut* 60:1506e1519.
229. von Wyl V, Kouyos RD, Yerly S, Böni J, Shah C, Bürgisser Ph, Klimkait T, Weber R, Hirschel B, Cavassini M, Staehelin C, Battegay M, Vernazza PL, Bernasconi E, Ledergerber B, Bonhoeffer S, Günthard HF, and the Swiss HIV Cohort Study (2011) The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. *J Infect Dis* 204: 1095-103.
230. Marzolini C, Back D, Weber R, Furrer HJ, Cavassini M, Calmy A, Vernazza P, Bernasconi E, Khoo S, Battegay M, Elzi L, and the Swiss HIV Cohort Study (2011) Aging with HIV: medications use and risk for potential drug-drug interactions. *JAIDS-J Acq Imm Def* 66:2107-11.
231. The Antiretroviral Therapy (ART) Cohort Collaboration (Writing Committee: Murray M, Hogg R, Lima V, May M, Moore D, Abgrall S, Bruyand M, D'Arminio Monforte A, Tural Cristina, Gill MJ, Reiss P, Justice A, Kirk O, Saag M, Smith C, Weber R, Rockstroh J, Khaykin P, Sterne J (2012) The effect of injection drug use history on disease progression and death among HIV-infected individuals initiation combination antiretroviral therapy. Collaborative Cohort Analysis. *HIV Med* 13:89-97.
232. Meier S, Weber R, Zbinden R, Ruef C, Hasse B (2011) Extended-spectrum beta-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: An increasing challenge for antimicrobial therapy. *Infection* 39:333-40.
233. Hasse B, Ledergerber B, Furrer HJ, Battegay M, Hirschel B, Cavassini M, Bertisch B, Bernasconi E, Weber R, and the Swiss HIV Cohort Study (2011) Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study. *Clin Infect Dis* 53:1130-39.
234. Metzner KJ, Leemann C, Di Giallonardo F, Grube C, Scherrer AU, Braun D, Kuster H, Weber R, Günthard HF (2011) Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection. *PLoS ONE* 6:e21734.
235. Viktor von Wyl<sup>1,2\*</sup>, Sara Gianella<sup>1,3</sup>, Marek Fischer<sup>1</sup>, Barbara Niederoest<sup>1</sup>, Herbert Kuster<sup>1</sup>, Manuel Battegay<sup>4</sup>, Enos Bernasconi<sup>5</sup>, Matthias Cavassini<sup>6</sup>, Andri Rauch<sup>7</sup>, Bernard Hirschel<sup>8</sup>, Pietro Vernazza<sup>9</sup>, Rainer Weber<sup>1</sup>, Beda Joos<sup>1</sup>, Huldrych F. Günthard<sup>1</sup>, the Swiss HIV Cohort Study (SHCS) (2011) Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption. *Plos One* 2011;6:e27463
236. Rieder P, Joos B, Scherrer A, Kuster H, Braun D, Grube C, Niederöst B, Leemann C, Gianella-Weibel S, Metzner KJ, Böni J, Weber R, Günthard HF (2011) Characterization of HIV-1 diversity and tropism in 145 patients with primary HIV-1 infection. *Clin Infect Dis* 53:1271-9.
237. Giner AM, Kuster SP, Zbinden R, Ruef C, Ledergerber B, Weber R (2011) Initial management of and outcome in patients with pneumococcal bacteremia: Retrospective Study at a Swiss University Hospital, 2003-2009. *Infection* 39:519-26.
238. Boillat Blanco N, Probst A, Waelti Da Costa V, Giulieri S, Bernasconi E, Calmy A, Elzi L, Rauch A, Weber R, Bertisch B, Cavassini M, Bochud PY (2011) Impact of a Nurse Vaccination Program on Hepatitis B Immunity in a Swiss HIV Clinic. *JAIDS-J Acq Imm Def* 2011;58:472-4.
239. Thierfelder C, Weber R, Elzi L, Furrer HJ, Cavassini M, Calmy A, Bernasconi E, Gutmann C, Ledergerber B, and the Swiss HIV Cohort Study (2012) Participation, characteristics, and retention rates of HIV-positive immigrants in the Swiss HIV Cohort Study. *HIV Med* 13:118-26.
240. Arenas-Pinto A, Weller I, Ekong R, Grant A, Karstaedt A, Reiss P, Telisinghe L, Weber R, Bolhaar M, Bradman N, Ingram C (2012) Common inherited mtDNA mutations and NRTI-induced severe hyperlactataemia in white European and black African HIV-infected adults: an exploratory study. *Antivir Ther* 17:275-82.
241. Staehelin CJ, Keiser O, Calmy A, Weber R, Elzi L, Cavassini M, Schmid P, Bernasconi E, Furrer HJ and the Swiss HIV Cohort Study (2012) Longer term clinical and virological outcome of Sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study. *JAIDS-J Acq Imm Def* 59:79-85.

242. Worm SW, Kamara DA, Reiss P, Fontas E, De Wit S, El-Sadr W, Monforte AD, Law M, Phillips A, Ryom L, Dabis F, Weber R, Sabin C, Lundgren JD, on behalf of the D:A:D Study Group (2012) Evaluation of HIV protease inhibitor usage and the risk of sudden death or non-haemorrhagic stroke. *J Infect Dis* 205:535-9.
243. Huber M, Ledergerber B, Sauter R, Young J, Fehr J, Cusini A, Battegay M, Calmy A, Orasch C, Nicca D, Bernasconi E, Jaccard R, Held L, Weber R, and the Swiss HIV Cohort Study (2012) Outcome of smoking cessation counselling of HIV-positive persons by HIV care physicians. *HIV Med.* 2012;13:387-97.
244. Young J, Schäfer J, Fux CA, Furrer HJ, Bernasconi E, Vernazza P, Calmy A, Cavassini M, Weber R, Battegay M, Bucher HC, and the Swiss HIV Cohort Study (2012) Renal function in patients with HIV starting a first therapy with tenofovir and either efavirenz, boosted lopinavir or boosted atazanavir: the Swiss HIV Cohort Study. *AIDS* 26:567-75.
245. Bucher HC, Richter W, Glass TR, Magenta L, Cavassini M, Vernazza P, Hirschel B, Weber R, Furrer H, Battegay M, Bernasconi E, and Swiss HIV Cohort Study (2012) Small dense lipoproteins, apolipoprotein B and risk of coronary events in HIV-infected patients on antiretroviral therapy: The Swiss HIV Cohort Study. *JAIDS-J Acq Imm Def* 2012;60(2):135-42.
246. Hunziker T, Berger C, Staubli G, Tschopp A, Weber R, Nadal D, Hatz C, Schlagenhauf P (2012) Profile of travel associated illness in children, Zürich, Switzerland. *J Travel Med*;19:158-162.
247. Savaria F, Zbinden R, Wüst J, Burnens A, Ledergerber B, Weber R, Kovari H (2012) Antibiotikaresistenzen von *E. coli* in Urinproben: Prävalenzdaten dreier Laboratorien im Raum Zürich von 1985 bis 2010. *PRAXIS* 101:573-9.
248. Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, D'Arminio Monforte A, Friis-Møller N, Lundgren JD, Law MG, on behalf of the D:A:D Study Group (2012) Predicting the short term risk of diabetes in HIV positive patients: The Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study. *J Int AIDS Soc.* 2012 Oct 10;15(2):17426.
249. Fröhlich Knaute D, Graf N, Lautenschlager S, Weber R, Bosshard PP (2012) Serological response to treatment of syphilis according to disease stage and HIV status. *Clin Infect Dis.* 2012;55:1615-22.
250. Elzi L, Erb S, Furrer HJ, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Weber R, Battegay M, and the Swiss HIV Cohort Study (2012) Choice of Initial Combination Antiretroviral Therapy in HIV-Infected Individuals: Determinants and Outcome. *Arch Intern Med.* 2012;172:1313-21.
251. Weber R\*, Ruppik M1\* (\* contributed equally), Rickenbach M, Spoerri A, Furrer HJ, Battegay M, Cavassini M, Calmy A, Bernasconi E, Schmid P, Flepp M, Kowalska J, Ledergerber B, and the Swiss HIV Cohort Study (SHCS) (2013) Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. *HIV Med* 14:195-207.
252. d'Arminio Monforte A, Reiss P, Ryom L, El-Sadr W, Dabis F, De Wit S, Worm S, Law MG, Weber R, Kirk O, Pradier C, Phillips AN, Lundgren JD, Sabin CA (2013) Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. *AIDS* 27:407-415.
253. Kovari H, Sabin CA, Ledergerber B, Ryom L, Worm SW, Smith C, Phillips A, Reiss P, Fontas E, Petoumenos K, De Wit S, Morlat P, Lundgren JD, Weber R (2013) Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of HBV or HCV co-infection. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. *Clin Infect Dis* 56:870-9.
254. Metzner KJ, Scherrer AU, Preiswerk B, Joos B, von Wyl V, Leeman C, Rieder P, Braun D, Grube C, Kuster H, Böni J, Yerly S, Klimkait T, Aubert V, Furrer H, Battegay M, Vernazza PL, Cavassini M, Calmy A, Weber R, Günthard HF, and the Swiss HIV Cohort Study (2013) Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. *J Infect Dis*;208:1102-12.
255. Rotger M, Glass TR, Junier T, Lundgren J, Neaton JD, Poloni ES, van 't Wout AB, Lubomirov R, Colombo S, Martinez R, Rauch A, Günthard HF, Neuhaus J, Wentworth D, van Manen D, Gras LA, Schuitemaker H, Albini L, Torti C, Jacobson LP, Li X, Kingsley LA, Carli F, Guaraldi G, Ford ES, Sereti I, Hadigan C, Martinez E, Arnedo-Valero M, Egaña-Gorroño L, Gatell JM, Law M; Bendall C, Petoumenos K, Rockstroh J, Wasmuth JC, Kabamba K, Delforge M, De Wit S, Berger F, Mauss S, de Paz Sierra M, Losso M, Belloso WH, Leyes M, Campins A, Mondì A, De Luca A, Bernardino I, Barriuso-Iglesias M, Torrecilla-Rodriguez A, Gonzalez-Garcia J, Arribas JR, Fanti I, Gel S, Puig J, Negro E, Gutierrez M, Domingo P, Fischer J, Fätkenheuer G, Alonso-Villaverde C, Macken A, Woo J, McGinty T, Mallon P, Mangili A, Skinner S, Wanke CA, Reiss P, Weber R, Bucher HC,

- Fellay J, Telenti A, Tarr PE, for the MAGNIFICENT Consortium†, INSIGHT‡ and the Swiss HIV Cohort Study (2013) Contribution of genetic background, traditional risk factors and HIV-related factors to coronary artery disease events in HIV-positive persons. *Clin Infect Dis* 57:112-21.
256. Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, Weber R, D'Arminio Monforte A, Reiss P, Kamara D, El-Sadr W, Pradier C, Dabis F, Law M, Lundgren J (2013) Associations between immune depression and cardiovascular events in HIV infection. *AIDS* 27:2735-48.
  257. Wolfensberger A, Sax H, Weber R, Zbinden R, Böttger EC, Kuster SP\*, Hombach M\* (\*contributed equally) (2013) Change of Antibiotic Susceptibility Testing Guidelines from CLSI to EUCAST: Influence on Cumulative Hospital Antibiograms. *PLOS One* 8:e79130.
  258. Wang Q, Young J, Bernasconi E, Cavassini M, Vernazza P, Hirschel B, Weber R, Furrer HJ, Stoeckle M, Bucher HC, Fux C, and the Swiss HIV Cohort Study (2013) The prevalence of erectile dysfunction and its association with antiretroviral therapy in HIV-infected men: The Swiss HIV Cohort Study. *Antivir Ther* 2013;18:337-44.
  259. Conen A, Wang Q, Glass TR, Fux CA, Thurnheer MC, Orasch C, Calmy A, Bernasconi E, Vernazza P, Weber R, Bucher HC, Battegay M, Fehr J, and the Swiss HIV Cohort Study (2013) Association of alcohol consumption and HIV surrogate markers in participants of the Swiss HIV Cohort Study. *JAIDS-J Acq Imm Def Syndr* 15;64:472-8.
  260. Kovari H, de Melo Oliveira M, Hauser P, Läubli S, Meyer J, Weber R, Zbinden R (2013) Decreased susceptibility of *Neisseria gonorrhoeae* isolates from Switzerland to cefixime and ceftriaxone: Antimicrobial susceptibility data from 1990 and 2000 to 2012. *BMC Infect Dis* 2013;13:603. doi: 10.1186/1471-2334-13-603
  261. Nüesch R, Wang Q, Elzi L, Bernasconi E, Weber R, Cavassini M, Vernazza P, Thurnheer MC, Calmy A, Battegay M, Bucher HC; Swiss HIV Cohort Study (2013) Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIC Cohort Study (SHCS) *J Acquir Immune Defic Syndr* 62:396-404.
  262. Young J, Wang Q, Fux CA, Bernasconi E, Furrer H, Vernazza P, Calmy A, Cavassini M, Weber R, Battegay M, Bucher HC, and the Swiss HIV Cohort Study (2014) The rate of recovery in renal function when patients with HIV discontinue treatment with tenofovir. *HIV Med* 15:505-10.
  263. Buetikofer S, Wandeler G, Kouyos R, Weber R, Ledergerber B (2014) Prevalence and Risk Factors of Late Presentation for HIV Diagnosis and Care in a Tertiary Referral Center in Switzerland. *Swiss Med Wkly* 2014;144:w13961.
  264. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska J, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, d'Arminio Monforte A, Phillips AN, Sabin CA, Lundgren JD, for the D:A:D Study Group (2014) Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. *Lancet* 384:241-48.
  265. Hasse B, Walker A, Fehr J, Furrer HJ, Hoffmann M, Battegay M, Calmy A, Fellay J, Di Benedetto C, Weber R, Ledergerber B (2014) Cotrimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study. *Antimicrob Agents Chemother* 58:2363-8.
  266. Braun DL, Rauch A, Durisch N, Eberhard N, Anagnostopoulos A, Ledergerber B, Böni J, Weber R, Fehr J (2014) Efficacy of lead-in silybinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfecting patients. *HIV Med* 15:625-30.
  267. Glatz M, Juricevic N, Altwegg M, Bruisten S, Komericki P, Lautenschlager S, Weber R, Bosshard PP (2014) A multicenter prospective trial to assess a new real-time polymerase chain reaction for detection of *Treponema pallidum*, herpes simplex-1/2 and *Haemophilus ducreyi* in genital, anal and oropharyngeal ulcers. *Clin Microbiol Infect* 20:O1020-7.
  268. Metzner KJ\*, Scherrer AU\*, von Wyl V\*, Leemann C, Böni J, Yerly S, Klimkait T, Aubert V, Furrer HJ, Battegay M, Vernazza PL, Cavassini M, Calmy A, Bernasconi E, Weber R, Günthard HF, and the Swiss HIV Cohort Study (2014) Limited clinical benefit of minority K103N- and Y181C-variant detection in addition to routine GRT in ART-naïve patients. *AIDS* 28:2231-9.
  269. Xiao Y, Abrahamowicz M, Moodie EEM, Weber R, Young J (2014) Flexible Marginal Structural Models for Estimating the Cumulative Effect of a Time-Dependent Treatment on the Hazard: Reassessing the Cardiovascular Risks of Didanosine Treatment in the Swiss HIV Cohort Study. *Journal of the American Statistical Association* 109:455-464.

270. Schlagenhauf P, Weld L, Goorhuis A, Gautret P, Weber R, von Sonnenburg F, Lopez-Vélez R, Jensenius M, Cramer JP, Field VK, Odolini S, Gkrania-Klotsas E, Chappuis F, Denis MalvyJM, van Genderen PJJ, Mockenhaupt F, Jauréguiberry S, Smith C, Beeching N, Ursing J, Parola P, Grobusch MP, for EuroTravNet (2015) Travel-associated infection presenting in Europe (2008-2012): an analysis of EuroTravNet longitudinal, surveillance data and evaluation of the impact of the pre-travel consultation. *Lancet Infect Dis* 15:55-64.
271. Weber R\*, Huber M\* (\*contributed equally), Battegay M, Stähelin C, Batanjer EC, Calmy A, Bregenzer A, Bernasconi E, Schoeni-Affolter F, Ledergerber B, and the Swiss HIV Cohort Study (2015) Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the Swiss HIV Cohort Study. *HIV Medicine* 16:137-51.
272. Sah BR, Husmann L, Mayer D, Scherrer A, Rancic Z, Puipe G, Weber R, Hasse B, and the VASGRA Cohort (2015) Diagnostic performance of 18F-FDG-PET/CT in vascular graft infections. *Eur J Vasc Endovas Surg* 49:455-64.
273. Sax H, Bloemberg G, Hasse B, Sommerstein R, Kohler P, Achermann Y, Rössle M, Falk V, Kuster SP, Böttger EC, Weber R (2015) Prolonged outbreak of *Mycobacterium chimaera* Infection after open chest heart surgery. *Clin Infect Dis* 61:67-75.
274. Young J, Xiao Y, Moodie EE, Abrahamowicz M, Klein MB, Bernasconi E, Schmid P, Calmy A, Cavassini M, Cusini A, Weber R, Bucher HC; Swiss HIV Cohort Study (2015) Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study. *J Acquir Immune Defic Syndr* 69:413-21.
275. Husmann L, Sah BR, Scherrer A, Rancic Z, Stolzmann P, Weber R, Mayer D, Hasse B, and the VASGRA Cohort (2015) 18F-FDG-PET/CT for therapy control in vascular graft infections: a first feasibility study. *J Nucl Med* 56:1024-9.
276. Kovari H, Ledergerber B, Cavassini M, Ambrosioni J, Bregenzer A, Stöckle M, Bernasconi E, Kouyos R, Weber R\*, Andri Rauch\* (\*contributed equally), and the Swiss HIV Cohort Study (2015) High Hepatic and Extrahepatic Mortality and Low Treatment Uptake in HCV-coinfected Persons in the Swiss HIV Cohort Study between 2001 and 2013. *J Hepatol* 2015 Sep;63(3):573-80.
277. Braun DL, Kouyos RD, Balmer B, Grube C, Weber R, Günthard HF (2015) Frequency and spectrum of unexpected clinical manifestations of primary HIV-1 infection. *Clin Infect Dis* 61:1013-21.
278. Leuthard D, Berger C, Staubli G, Nadal D, Schmid S, Hamer D, Weber R, Schlagenhauf (2015) Management of Children with Travel-Related Illness Evaluated in a Pediatric Emergency Room. *Pediatr Infect Dis J*. 2015 Dec;34(12):1279-82].
279. Kouyos R, Hasse B, Calmy A, Cavassini M, Furrer HJ, Battegay M, Vernazza PL, Bernasconi E, Weber R, Günthard HF (2015) Increases in condom-less sex in the Swiss HIV cohort study. *Open Forum Infectious Diseases* 2015 Jun 3;2(2):ofv077. doi: 10.1093/ofid/ofv077. eCollection 2015 Apr.
280. Beeler PE, Kuster SP, Eschmann E, Weber R, Blaser J (2015) Earlier switching from intravenous to oral antibiotics due to electronic reminders. *Int J Antimicrobial Agents* 46:428-33.
281. Braun DL, Rauch A, Aouri M, Durisch N, Eberhard N, Anagnostopoulos A, Ledergerber B, Müllhaupt B, Metzner KJ, Decosterd L, Böni J, Weber R, Fehr J (2015) A lead-in with silibinin prior to triple-therapy translates into favorable treatment outcomes in difficult-to-treat HIV/hepatitis C coinfecting patients. *PLoS ONE* 10(7): e0133028.
282. Kohler P, Kuster SP, Bloemberg G, Schulthess B, Frank M, Tanner FC, Rössle M, Böni C, Falk V, Wilhelm MJ, Sommerstein R, Achermann Y, ten Oever J, Debast SB, Wolfhagen MJHM, Brandon GJ, Bruinsma B, Vos MC, Bogers A, Serr A, Beyersdorf F, Sax H, Böttger EC, Weber R, van Ingen J\*, Wagner D\*, Hasse B (2015) Health-care associated prosthetic heart valve, aortic vascular graft, and disseminated *Mycobacterium chimaera* infections subsequent to open heart surgery. *Eur Heart J* 36:2745-53.
283. Hasse B, Tarr PE, Marques-Vidal P, Waeber G, Preisig M, Mooser V, Valeri F, Djalali S, Burton-Jeangros C, Rauch A, Bernasconi E, Calmy A, Cavassini M, Vernazza P, Battegay M, Weber R, Senn O, Vollenweider P, Ledergerber B, and the CoLaus Cohort, FIRE and the Swiss HIV Cohort Study (2015) Strong impact of smoking on multimorbidity and cardiovascular risk among HIV infected individuals in comparison to the general population. *Open Forum Infectious Diseases* 2015 Jul 8;2(3):ofv108. doi: 10.1093/ofid/ofv108. eCollection 2015.
284. Bihl F, Martinetti G, Wandeler G, Weber R, Ledergerber B, Calmy A, Battegay M, Cavassini M, Vernazza P, Caminada AP, Rickenbach M, Bernasconi E, and Swiss HIV Cohort Study (2015)

- HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons. *BMC Gastroenterology* 15:79. doi: 10.1186/s12876-015-0308-0.
285. Schmid P, Bregenzler A, Huber M, Rauch A, Jochum W, Müllhaupt B, Vernazza P, Opravil M, Weber R, and the Swiss HIV Cohort Study (2015) Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy. *PLoS One* 2015 Sep 29;10(9):e0138838. doi: 10.1371/journal.pone.0138838. eCollection 2015
  286. Anagnostopoulos A\*, Ledergerber B\* (Co-first authors), Jaccard R, Shaw SA, Stöckle M, Bernasconi E, Barth J, Calmy A, Berney A, Jenewein J, Weber R, and the Swiss HIV Cohort Study (2015) Frequency of and Risk Factors for Depression among Participants in the Swiss HIV Cohort Study (SHCS). *PlosOne* 2015 Oct 22;10(10):e0140943. doi: 10.1371/journal.pone.0140943. eCollection 2015.
  287. Hachfeld A, Ledergerber B, Darling K, Weber R, Calmy A, Battegay M, Sugimoto K, Di Benedetto C, Fux CA, Tarr P, Kouyos R, Furrer HJ, Wandeler G, and the Swiss HIV Cohort Study (2015) Reasons for late HIV-testing and presentation to care in Switzerland. *J Int AIDS Soc* 2015 Nov 18;18(1):20317. doi: 10.7448/IAS.18.1.20317. eCollection 2015.
  288. Meloni M\*, Corti N\*, Muller D, Henning L, Gutteck U, Von Braun A, Weber R, Fehr J. Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges: *Swiss Med Wkly* 2015 Dec 23;145:w14223. doi: 10.4414/smw.2015.14223. eCollection 2015.
  289. Friis-Møller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, De Wit S, D'Arminio Monforte A, Kirk O, Fontas E, Sabin C, Phillips A, Lundgren J, Law M, on behalf of the D:A:D study group (2016) An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons. *Eur J Prev Cardiol* 2016; 214-23.
  290. Kovari H., Sabin CA, Ledergerber B, Ryom L, Reiss P, Law M, Pradier C, Dabis F, d'Arminio Monforte A, Smith C, de Witt S, Kirk O, Lundgren J, Weber R, on behalf of the D:A:D Study group (2015) Antiretroviral drugs and risk of chronic ALT elevation in HIV-monoinfected persons without viral hepatitis coinfection. *The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. Open Forum Infect Dis.* 2016 Jan 21;3(1):ofw009. doi: 10.1093/ofid/ofw009. eCollection 2016 Jan.
  291. Achhra AC, Mocroft A, Reiss P, Sabin CA, Ryom L, de Wit S, Smith CJ, Monforte AD, Phillips A, Weber R, Lundgren JD, Law MG, (2016) The D:A:D Study Group. Short-term change in body mass index after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes in HIV-positive individuals: the D:A:D study. *HIV Medicine* 2016 Apr;17(4):255-68.
  292. Hatleberg CI, Ryom L, Smith C, El-Sadr W, Weber R, Reiss P, Fontas E, Dabis F, Law M, d'Arminio Monforte A, de Wit S, Mocroft A, Phillips A, Lundgren J, Sabin C, for the D:A:D Study Group (2016) Improvements over time in short-term mortality following myocardial infarction in the D:A:D Study. *AIDS.* 2016;30(10):1583-96.
  293. Sabin C, Reiss P, Ryom L, Phillips A, Weber R, Law M, Fontas E, Mocroft A, de Wit S, Smith C, Dabis F, d'Arminio Monforte A, El-Sadr W, Lundgren J, for the D:A:D Study Group (2016) Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. *BMC Med.* 2016 Mar 31;14(1):61. doi: 10.1186/s12916-016-0588-4.
  294. Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Van Lunzen J, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Asboe D, Viciano P, Gutiérrez F, Clotet B, Pradier C, Gerstoft J, Weber R, Westling K, Wandeler G, Prins JM, Rieger A, Stoeckle M, Kümmerle T, Bini T, Ammassari A, Gilson R, Krznaric I, Ristola M, Zangerle R, Handberg P, Antela A, Allan S, Phillips AN, Lundgren J, for the PARTNER Study Group (2016) Association between sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy: The PARTNER STUDY. *JAMA-J Am Med Assoc* 2016;316:171-81.
  295. Junier T, Rotger M, Biver E, Ledergerber B, Barceló C, Bartha I, Kovari H, Vernazza P, Fux C, Bernasconi E, Brun Del Re C, Weber R, Fellay J, Tarr PE, and the Swiss HIV Cohort Study (2016) Contribution of Genetic Background and Clinical Risk Factors to Low-Trauma Fractures in Human Immunodeficiency Virus (HIV)-Positive Persons: The Swiss HIV Cohort Study. *Open Forum Infect Dis.* 2016;3(2):ofw101. doi: 10.1093/ofid/ofw101. eCollection 2016.
  296. Kovari H, Rauch A, Calmy A, Cavassini M, Schmid P, Stöckle M, Bernasconi E, Weber R, Ledergerber B, and the Swiss HIV Cohort Study (2017) Hepatitis C infection and the risk of non-liver-related morbidity and mortality in HIV-positive persons in the Swiss HIV Cohort Study. *Clin Infect Dis* 15;64:490-497.

297. Borges ÁH, Hoy J, Florence E, Sedlacek D, Stellbrink HJ, Uzdaviniene V, Tomazic J, Gargalianos-Kakolyris P, Schmid P, Orkin C, Pedersen C, Leen C, Pradier C, Mulcahy F, Ridolfo AL, Staub T, Maltez F, Weber R, Flamholz L, Kyselyova G, Lundgren JD, Mocroft A; for EuroSIDA (2017) Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort. *Clin Infect Dis* 15;64:1413-1421.
298. Nemeth J, Vongrad V, Metzner KJ, Strouvelle VP, Weber R, Pedrioli P, Aebersold R, Günthard HF, Collins BC (2017) In Vivo and in Vitro Proteome Analysis of Human Immunodeficiency Virus (HIV)-1-infected, Human CD4<sup>+</sup> T Cells. *Mol Cell Proteomics* 2017 (4 suppl 1):S108-S123. doi: 10.1074/mcp.M116.065235. Epub 2017 Feb 21.
299. Akers IE, Weber R, Sax H, Böni J, Trkola A, Kuster SP. (2017) Influence of time to diagnosis of severe influenza on antibiotic use, length of stay, isolation precautions, and mortality: a retrospective study. *Influenza Other Respir Viruses* 11(4):337-344.
300. Bayard B, Ledergerber B, Flepp M, Lecompte T, Moulin E, Hoffmann M, Weber R, Staehelin C, Di Benedetto C, Fux CA, Tarr PE, Hasse B, and the Swiss HIV Cohort (2017) Associations between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study. *Open Forum Infectious Diseases*. *Open Forum Infect Dis*. 2017 Aug 22;4(4):ofx177. doi: 10.1093/ofid/ofx177. eCollection 2017
301. Sabin CA, Lene R, d'Arminio Monforte A, Hatleber C, Pradier C, El-Sadr W, Kirk O, Weber R, Philipps AN, Mocroft A, Bonnet F, Law M, De Witt S, Reiss P, Lundgren JD, for the D:A:D Study Group (2017) Abacavir use and risk of recurrent myocardial infarction: the D:A:D Study. *AIDS*. 2018;32:79-88.
302. Boyd MA, Mocroft A, Ryom L, d'Arminio Monforte A, Sabin C, El-Sadr WM, Hatleberg CI, De Wit S, Weber R, Fontas E, Phillips A, Bonnet F, Reiss P, Lundgren J, Law M. Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. *PLoS Med* 2017;14(11):1002424.
303. Tarr PE, Ledergerber B, Doco-Lecompte T, Calmy A, Marzel A, Weber R, Kaufmann PA, Nkoulou R, Buechel RR\*, Kovari H\*, and the Swiss HIV Cohort Study. Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative persons. *Eur Heart J*. 2018;39:2147-2154,
304. Marzel A, Kouyos RD, Reinschmidt S, Balzer K, Garon F, Spitaleri M, Matthes N, Suter P, Weber R, Staehelin C, Lecompte TD, Tarr P, Kovari H; and the Swiss HIV Cohort Study.and the Swiss HIV Cohort Study. Dietary Patterns and Physical Activity Correlate With Total Cholesterol Independently of Lipid-Lowering Drugs and Antiretroviral Therapy in Aging People Living With Human Immunodeficiency Virus. *Open Forum Infect Dis* 2018 Mar 23;5(4):ofy067. doi: 10.1093/ofid/ofy067.
305. Ryom L, Lundgren JD, El-Sadr W, Reiss P, Kirk O, Law M, Phillips A, Weber R, Fontas E, d' Arminio Monforte A, De Wit S, Dabis F, Hatleberg C, Sabin C, Mocroft A; D:A:D study group. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. *Lancet HIV* 2018:e291-e300. doi: 10.1016/S2352-3018(18)30043-2.
306. Reinschmidt S, Turk T, Tarr PE, Kouyos R, Staehelin C, Schmid P, Weber R, Kaufmann Ph, Büchel R, Kovari H, and the Swiss HIV Cohort Study. Incidental findings on coronary computed tomography angiography in HIV-positive and HIV-negative persons. *Open Forum Infect Dis*. 2018 Apr 20;5(5):ofy084. doi: 10.1093/ofid/ofy084.
307. Ronit A, Hatleberg CI, Ryom L, Bonnet F, El-Sadr W, Reiss P, Weber R, Pradier C, De Wit S, Law M, d'Arminio Monforte A, Lundgren J, Mocroft A, Phillips AN, Sabin CA; D:A:D Study Group. Associations between serum albumin and serious non-AIDS events among people living with HIV. *AIDS* 2018 Aug 24;32(13):1837-1848. doi: 10.1097/QAD.0000000000001900.
308. Hatleberg CI, Ryom L, d'Arminio Monforte A, Fontas E, Reiss P, Kirk O, El-Sadr W, Phillips A, de Wit S, Dabis F, Weber R, Law M, Lundgren JD, Sabin C; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV-positive persons: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. *HIV Med*. 2018 Oct;19(9):605-618. doi: 10.1111/hiv.12639
309. Marzel A, Kusejko K, Weber R, Bruggmann P, Rauch A, Roth JA, Bernasconi E, Calmy A, Cavassini M, Hoffmann M, Böni J, Yerly S, Klimkait T, Perreau M, Günthard HF, Kouyos RD; Swiss HIV Cohort Study. The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis. *Open Forum Infect Dis*. 2018 May 19;5(5):ofy078. doi: 10.1093/ofid/ofy078. eCollection 2018 May.



310. Achhra AC, Sabin C, Ryom L, Hatleberg C, Antonella d'Aminio M, de Wit S, Phillips A, Pradier C, Weber R, Reiss P, El-Sadr W, Bonnet F, Mocroft A, Lundgren J, Law MG; D:A:D Study Group. Body Mass Index and the Risk of Serious Non-AIDS Events and All-Cause Mortality in Treated HIV-Positive Individuals: D: A: D Cohort Analysis. *J Acquir Immune Defic Syndr*. 2018 Aug 15;78(5):579-588. doi: 10.1097/QAI.0000000000001722.
311. Shepherd L, Ryom L, Law M, Petoumenos K, Hatleberg CI, d'Arminio Monforte A, Sabin C, Bower M, Bonnet F, Reiss P, de Wit S, Pradier C, Weber R, El-Sadr W, Lundgren J, Mocroft A; D:A:D Study group. Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. *Clin Infect Dis*. 2019;68:650-57.
312. Hachfeld A, Darling K, Calmy A, Ledergerber B, Weber R, Battegay M, Wissel K, Di Benedetto C, Fux CA, Tarr PE, Kouyos R, Ruggia LS, Furrer HJ, Wandeler G, and the Swiss HIV Cohort Study. Why do sub-Saharan Africans present late for HIV care in Switzerland? *HIV Med*. 2019 Jul;20(6):418-423.
313. Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Raben D, Coll P, Antinori A, Nwokolo N, Rieger A, Prins JM, Blaxhult A, Weber R, Van Eeden A, Brockmeyer NH, Clarke A, Del Romero Guerrero J, Raffi F, Bogner JR, Wandeler G, Gerstoft J, Gutiérrez F, Brinkman K, Kitchen M, Ostergaard L, Leon A, Ristola M, Jessen H32, Stellbrink HJ, Phillips AN, Lundgren J; PARTNER Study Group. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. *Lancet*. 2019 Jun 15;393(10189):2428-2438. doi: 10.1016/S0140-6736(19)30418-0. Epub 2019 May 2.
314. Schwarz H; Böni J; Kouyos RD; Turk T; Battegay E; Kohler M; Müller R; Petry H; Sax H; Weber R; McGeer A; Trkola A; Kuster SP. The TransFLUas influenza transmission study in acute healthcare - recruitment rates and protocol adherence in healthcare workers and inpatients M.D., M.Sc. *BMC Infectious Diseases* 2019;19:446
315. Lenherr Ramos L, Weber R, Sax H, Giovanoli P, Kuster SP. A Comprehensive Unit-based Safety Program for the Reduction of Surgical Site Infections in Plastic Surgery and Hand Surgery. *Infect Control Hosp Epidemiol*. 2019 Oct 14:1-7. doi: 10.1017/ice.2019.279.
316. Ryom L, Lundgren JD, Law M, Kirk O, El-Sadr W, Bonnet F, Weber R, Fontas E, Monforte AD, Phillips A, Reiss P, de Wit S, Hatleberg CI, Sabin C, Mocroft A; D:A:D study group. Serious clinical events in HIV-positive persons with chronic kidney disease. *AIDS*. 2019 Nov 15;33(14):2173-2188.
317. Kovari H, Calmy A, Doco-Lecompte T, Nkoulou R, Marzel A, Weber R, Kaufmann PA, Buechel RR, Ledergerber B, Tarr PE; Swiss HIV Cohort Study. Antiretroviral Drugs Associated with Subclinical Coronary Artery Disease in the Swiss HIV Cohort Study. *Clin Infect Dis*. 2020;70:884-9.
318. Kusejko K, Marzel A, Nguyen H, Chaudron SE, Bachmann N, Weber R, Bruggmann P, Roth JA, Bernasconi E, Calmy A, Cavassini M, Bregenzler A, Böni J, Yerly S, Klimkait T, Perreau M, Walti LN, Günthard HF, Kouyos RD, and the Swiss HIV Cohort Study. Differences in social and mental well-being of long-term survivors among people who inject drugs and other participants in the Swiss HIV Cohort Study: 1980 – 2018. *Antivir Ther* 2020;25(1):43-54.
319. Tarr PE, Ledergerber B, Calmy A, Doco-Lecompte T, Schoepf IC, Marzel A, Weber R, Kaufmann PA, Nkoulou R, Buechel RR, Kovari H, and the Swiss HIV Cohort Study. Longitudinal Progression of Subclinical Coronary Atherosclerosis in Swiss HIV-Positive Compared With HIV-Negative Persons Undergoing Coronary Calcium Score Scan and CT Angiography. *Open Forum Infect Dis* 2020;7:ofaa438.
320. Kuster SP, Böni J, Kouyos RD, Huber M, Schmutz S, Shah C, Bischoff-Ferrari HA, Distler O, Battegay E, Giovanoli P, Guckenberger M, Kohler M, Müller R, Petry H, Ruschitzka F, McGeer A, Coleman BL, Sax H, Weber R, Trkola A. Absenteeism and presenteeism in healthcare workers due to respiratory illness. *Infect Control Hosp Epidemiol*. 2021 Mar;42(3):268-273. doi: 10.1017/ice.2020.444.
321. Petoumenos K, Kuwanda L, Ryom L, Mocroft A, Reiss P, De Wit S, Pradier C, Phillips A, Hatleberg CI, d'Arminio Monforte A, Weber R, A Sabin CA, Lundgren J, G Law MG for the D:A:D Study group. Effect of changes in body mass index on the risk of cardiovascular disease and diabetes mellitus in HIV-positive individuals: results from the D:A:D study. *J Acquir Immune Defic Syndr* 2021;86(5):579-586.

322. Boettiger DC, Newall AT, Phillips A, Bendavid E, Law MG, Ryom L, Reiss P, Mocroft A, Bonnet F, Weber R, El-Sadr W, d'Arminio Monforte A, de Wit S, Pradier C, Ingrid Hatleberg C, Lundgren J, Sabin C, Kahn JG, Kazi DS. Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States. *J Int Aids Soc* 2021, 24:e25690. <https://doi.org/10.1002/jia2.25690>
323. Tamò R, Turk T, Böni J, D Kouyos RD, Schmutz S, Huber M, Shah C, Bischoff-Ferrari HA, Distler O, Battegay E, Giovanoli P, Guckenberger M, Kohler M, Müller R, Petry H, Ruschitzka F, McGeer A, Sax H, Weber R, Trkola A, Kuster SP. Secondary attack rates from asymptomatic and symptomatic influenza virus shedders in hospitals: Results from the TransFLUas influenza transmission study. *Infect Control Hosp Epidemiol*. 2021 May 6;1-7. doi: 10.1017/ice.2021.112. Online ahead of print.
324. Chok L, Kusejko K, Eberhard N, Chaudron SE, Saleschus D, Kocher C, Kouyos RD, Weber R, Kuster SP. Impact of an electronic alert on prescription patterns of meropenem, voriconazole and caspofungin. *BMC Infect Dis*. 2021 Dec 20;21(1):1263. doi: 10.1186/s12879-021-06980-1.

### B) Case Reports (peer reviewed, original)

325. Weber R, Budmiger H, Siegenthaler W (1988) Die chronische Formaldehydimmission - ein verkanntes Krankheitsbild? *Schweiz med Wschr* 118:457-61.
326. Meyer BJ, Weber R, Jenzer HR, Jenni R, Conen D, Turina M (1990) Rapid growth and recurrence of atrial myxomas in two patients with swiss syndrome. *Am Heart J* 120:220-22.
327. Schwartz DA, Visvesvara GS, Weber R, Bryan RT (1994) Male genital tract microsporidiosis and AIDS: Prostatic abscess due to *Encephalitozoon hellem*. *J Euk Microbio* 41:61S
328. Bachmann S, Schnyder U, Pfyffer GE, Lüthy R, Weber R (1996) *Mycobacterium haemophilum*-Infektion bei einem Patienten mit AIDS. *Deut Med Wochenschr* 121:1189-92.
329. Zbinden R, Baumann Kurer S, Altwegg M, Weber R (1996) Generalized infection with *Bartonella henselae* following infection due to Epstein-Barr virus. *Clin Infect Dis* 23:1184-85.
330. Fleisch F, Pfyffer GE, Thüring Ch, Lüthy R, Weber R (1997) Zervikale Lymphadenitis bei einem immunkompetenten Patienten: ist *Mycobacterium gordonae* die Ursache? *Deut Med Wochenschr* 122:51-53.
331. Dudle G, Opravil M, Lüthy R, Weber R (1997) Meningitis nach akuter *Borrelia burgdorferi*-Infektion und HIV-Infektion. *Deut Med Wochenschr* 122:1178-80.
332. Ruggli GM, Weber R, Messmer EP, Font RL, Moll C, Bernauer W (1997) *Pneumocystis carinii* infection of the conjunctiva in a patient with acquired immune deficiency syndrome. *Ophthalmology* 104:1853-56.
333. Reichenberger F, Cathomas G, Weber R, Schoenenberger R, Tamm M (2001) Recurrent fever and pulmonary infiltrates in an HIV-positive patient (Clinico-Pathological Conference). *Respiration* 68:548-54
334. Zingg W, Renner-Schneiter EC, Pauli-Magnus C, Renner EL, van Overbeck J, Schläpfer E, Weber M, Weber R, Opravil M, Gottstein B, Speck RF (2004) Alveolar echinococcosis of the liver in an adult with human immunodeficiency virus type-1 infection. *Infection* 2004;32:299-302.
335. Jeker K, Weber R, Schulthess G, Furrer J (2005) Multilokuläre grosse Erytheme und Fieber. Fallbericht. *Schweiz Rundsch Med Prax* 94:1815-1819.
336. Schraner C, Hasse B, Hasse U, Baumann D, Faeh A, Burg G, Grimm F, Mathis A, Weber R, Günthard HF (2005) Successful treatment of disseminated cutaneous leishmaniasis with miltefosine in a severely immunocompromised HIV-infected patient. *Clin Infect Dis* 40:e120-4.
337. Gämperli A, Bosshard PP, Sigrist T, Brändli O, Wildermuth S, Weber R, Mueller NJ (2005) Pulmonary *Mycobacterium sherrisii* infection in a Human Immunodeficiency Virus Type-1-infected patient. *J Clin Microbiol* 43:4283-4285.
338. Georgi A, Schneemann M, Tintelnot K, Calligaris-Maibach RC, Meyer S, Weber R, Bosshard PP (2009) *Cryptococcus gattii* meningoencephalitis in an immunocompetent person thirteen months after exposure. *Infection* 37:370-3.
339. Cusini A, Günthard H, Weber R, Huber M, Kamarashev J, Bertisch B, Peter S, Beck B (2009) Lepromatous leprosy with erythema nodosum leprosum as immune reconstitution inflammatory

syndrome in an HIV-1-infected patient after initiation of antiretroviral therapy. *BMJ Case Reports* 2009;published online 1 December 2009, doi:10.1136/bcr.05.2009.1904  
[\(http://casereports.bmj.com/\)](http://casereports.bmj.com/)

340. Kocher C, Weber R, Friedl A (2011) A case study of female genital tuberculosis in a Western European setting. *Infection* 39:59-73.
341. Schärer V, Hafner R, Ciurea A, Henning L, Somoskövi A, Weber R, Fehr J (2014) Grenzen der Medizin: Diagnostik und Therapie von «entzündlichen» Rückenschmerzen (Limitations of Medicine: Diagnosis and Therapy of «Inflammatory» Back Pain). *PRAXIS* 103 (6): 337–40.
342. Kohler Ph, Clemns RK, Weber R (2015) Aufflammen des heiligen Feuers. *Swiss Med Forum* 15:758-59.

### C) Review Articles

343. Weber R, Bonetti A, Jost J, Lüthy R (1989) Aerztliche Beratung und Betreuung HIV-Positiver - Sekundäre individuelle Prophylaxe HIV-Infizierter. *Schweiz med Wschr* 119:251-8.
344. Eckert J, Jacquier P, Weber R (1990) Intestinale Protozoen - neue Aspekte. *Internist* 31:386-98.
345. Weber R, Jost J, Lüthy R, Siegenthaler R (1990) HIV-assoziierte opportunistische Erkrankungen: Diagnostische und therapeutische Möglichkeiten in Klinik und Praxis. *Internist* 31:553-66.
346. Weber R, Lüthy R (1991) Sekundärprophylaxe bei HIV-Infektion. *Ther Umsch* 48:258-63.
347. Weber R, Bryan RT, Schwartz DA, Owen RL (1994) Human microsporidial infections. *Clin Microbiol Rev* 7: 426-61.
348. Weber R, Bryan RT (1994) Microsporidial infections in immunodeficient and immunocompetent patients. *Clin Infect Dis* 19: 517-21
349. Schwartz DA, Bryan RT, Weber R, Visvesvara GS (1994) Microsporidiosis in HIV positive patients: Current methods for diagnosis using biopsy, cytologic, ultrastructural, immunological, and tissue culture techniques. *Folia Parasitologica* 41:101-9
350. Weber R, Deplazes P (1995) Neue parasitäre Erkrankungen beim Menschen: Infektionen durch Mikrosporidien und *Cyclospora* sp. *Schweiz med Wschr* 125:909-23
351. Weber R. Renaissance von Infektionskrankheiten (1996). P.A.F. Schweizerische Zeitschrift für permanente ärztliche Fortbildung 17:5-27
352. Weber R, Mathis A, Deplazes P (1996) Intestinale und systemische Infektionen durch Mikrosporidien. *Internist* 37:912-18
353. Jost J, Flepp M, Vernazza P, Battegay M, Kaiser L, Weber R, Bernasconi E (1998) Antiretrovirale HIV-Therapie. Empfehlungen 1998. *BAG Bull No.* 44:5-9
354. Flepp M, Jost, J, Hirschel B, Weber R, Bernasconi E für die Subkommission Klinik (SKK) der eigenössischen Kommission für Aidsfrage (EKAF) (2001) Empfehlungen zur antiretroviralen HIV-Therapie 2001. *BAG Bull No.* 51:994-1000
355. Flepp M, Schiffer V, Weber R, Hirschel B (2001) Modern Anti-HIV Therapy. *Swiss Medical Weekly* 131:207-13
356. Mathis A, Deplazes P, Weber R (2002) Mikrosporidien: intrazelluläre Eukaryoten und opportunistische Krankheitserreger. *Denisia* 6 184:265-70
357. Mathis A, Weber R, Deplazes P (2005) The Zoonotic Potential of the Microsporidia. *Clin Microbiol Rev* 18:423-445.
358. Evison J, Aebi C, Francioli P, Péter O, Bassetti S, Gervaix A, Zimmerli S, Weber R (2005) Abklärung und Therapie der Lyme-Borreliose bei Erwachsenen und Kindern: Empfehlungen der Schweizerischen Gesellschaft für Infektiologie. Teil 1: Epidemiologie und Diagnostik. *Schweiz. Ärztezeitung* 86:2332-2338. und *Rev. Med. Suisse* 2006;2:919-24.
359. Evison J, Aebi C, Francioli P, Péter O, Bassetti S, Gervaix A, Zimmerli S, Weber R (2005) Abklärung und Therapie der Lyme-Borreliose bei Erwachsenen und Kindern: Empfehlungen der Schweizerischen Gesellschaft für Infektiologie. Teil 2: Klinik und Therapie. *Schweiz. Ärztezeitung* 86:2375-2384. und *Rev. Med. Suisse* 2006;2:925-34.

360. Evison J, Aebi C, Francioli P, Péter O, Bassetti S, Gervaix A, Zimmerli S, Weber R (2005) Abklärung und Therapie der Lyme-Borreliose bei Erwachsenen und Kindern: Empfehlungen der Schweizerischen Gesellschaft für Infektiologie. Teil 3: Prävention, Schwangerschaft, Immundefizienz, Post-Lyme Syndrom. *Schweiz. Ärztezeitung* 86:2422-2428. und *Rev. Med. Suisse* 2006;2:935-40.
361. Hürlimann D, Weber R, Enseleit F, Lüscher TF (2005) HIV-Infektion, antiretrovirale Therapie und Endothel. *Herz* 30:472-80.
362. Sudano I, Spieker LE, Noll G, Corti R, Weber R, Lüscher TF (2006) Cardiovascular Disease in HIV-infection. *Am Heart J*;151:1147-55.
363. Samuel D, Weber R, Stock P, Duclos-Vallée JC, Terrault N (2008) Are HIV-infected patients candidates for liver transplantation? *J Hepatol* 48:697-707
364. Kovari H; Weber R (2011) Influence of Antiretroviral Therapy on Liver Disease. *Curr Opin HIV AIDS* 4:272-7.
365. Hasse B, Husmann L, Zinkernagel A, Weber R, Lachat L, Mayer D (2013) Vascular graft infections. *Swiss Med Wkly.* 2013;143:w13754
366. von Braun A, Furrer HJ, Battegay M, Calmy A, Cavassini M, Vernazza P, Bernasconi E, Weber R, Günthard HF (2014) Antiretrovirale Therapie. *Ther Umsch* 71:461-8.
367. Staehelin C, Elzi L, Weber R, Furrer HJ (2014) Therapie und Prävention von opportunistischen Infektionen. *Ther Umsch* 71:475-82.
368. von Braun A, Sommerstein R, Weber R, Fehr J (2014) Pneumonie beim Erwachsenen. Teil 1: Die ambulant erworbene Pneumonie. *Schweiz Med Forum* 14:560–565.
369. Sommerstein R, von Braun A, Weber R, Fehr J (2014) Pneumonie beim Erwachsenen. Teil 2: Die im Spital erworbene Pneumonie. *Schweiz Med Forum* 14:590–593.
370. Nemeth J, Weber R (2014) Endokarditisprophylaxe in der Zahnmedizin. *Zeitschr Dentalhyg.* 2014
371. Nemeth J, Bernasconi E, Heining U, Abbas M, Nadal D, Strahm C, Erb S, Zimmerli S, Furrer H, Delaloye J, Kuntzer T, Altpeter E, Sturzenegger M, Weber R, for the Swiss Society for Infectious Diseases and the Swiss Society for Neurology: Post-treatment Lyme disease syndrome. *Swiss Med Wkly.* 2016;146:w14353
372. Rüegg C; Tarnutzer A, Kuster SP, Weber R; Berger C; Zinkernagel AS. Streptococcus pyogenes – Kolonisation versus Virulenz. *Swiss Med Forum* 2018;18(33):647-653.
373. Weber R. Die anderen Zecken-übertragenen Infektionen in Mitteleuropa. *Ther Umsch* 2022 (accepted).

#### D) Editorials

374. Bryan RT, Weber R (1993) Microsporidia: Emerging pathogens in immunodeficient persons. [Editorial] *Arch Pathol Lab Med* 117:1243-45.
375. Weber R, Michel BA (2006) Infection in rheumatism patients [Editorial] *Zeitschr Rheumatologie* 65:6.
376. Weber R, Günthard HF (2014) HIV Infektion heute (Editorial). *Therapeutische Umschau* 71: 433-5.
377. Weber R (2022) Intestinale Spirochäten: Fälschlicherweise übersehen? Ursache von Reizdarmbeschwerden? oder bedeutungslos? (Editorial). *Swiss Medical Forum* (in press).

#### E) Book Chapters

378. Weber R, Schwartz D, Deplazes P. Laboratory diagnosis of microsporidiosis, p. 315-362. In: Wittner M (ed.) *The microsporidia and microsporidiosis*. American Society for Microbiology, ASM Press, Washington D.C. 1999
379. Weber R. Epidemiologie und Diagnostik von Kryptosporidien, Mikrosporidien und Cyclospora, p. 267-274. In: Kirchner T, Lembcke B, Kist M (eds.) *Ökosystem Darm VIII*. Springer-Verlag Berlin 1999

380. Weber R, Canning EU. Microsporidia, p. 1413-1420. In: Murray PR, Baron EJ, Pfaller MA, Tenoer FC, Tenover FC, Tenover FC (eds.) *Manual of Clinical Microbiology*. American Society for Microbiology, 7th Edition, ASM Press, Washington D.C. 1999
381. Weber R. Intestinal coccidia and microsporidia, p. 32.1-32.8. In: Armstrong D, Cohen J (eds.) *Infectious Diseases*. Mosby, London 1999
382. Bryan RT, Weber R, Schwartz DA. Microsporidiosis, p. 840-851. In: Guerrant RL, Walker DH, Weller PF (eds.) *Tropical Infectious Diseases: Principles, Pathogens and Practice*. Churchill Livingstone, Philadelphia 1999
383. Schwartz DA, Weber R, Bryan RT. Microsporidiosis, p. 625-643. In: Gilles (ed.) *Protozoal Diseases*. Arnold, London 1999
384. Weber R, Schwartz DA, Bryan RT. Microsporidia, p. 2920-2933. In: Mandell GL, Bennett JE, Dolin R (eds.) *Principles and Practice of Infectious Diseases*. Churchill Livingstone, New York 2000
385. Weber R, Lüthy R, Fontana A, Siegenthaler W. Status febrilis, p. 86-173. In: W. Siegenthaler (ed.) *Differentialdiagnose innerer Krankheiten*. Georg Thieme Verlag, Stuttgart 2000
386. Deplazes P, Mathis A, Weber R. Epidemiology and zoonotic aspects of Microsporidia of mammals and birds. *Contrib. Microb. Basel*, Karger, 2000, vol 6: 236-260
387. Weber R, Deplazes P, Schwartz D. Diagnosis and clinical aspects of human microsporidiosis. *Contrib. Microb. Basel*, Karger, 2000, vol 6: 166-192
388. Weber R. Treatment of microsporidial infections, p. 1585-1593. In: Yu V, Weber R, Raoult D (eds.) *Antimicrobial Therapy and Vaccines, Volume I: Microbes*. Apple Trees Productions, New York 2002
389. Weber R, Canning EU. Microsporidia, p.2020-2030. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Tenover FC, Tenover FC (eds.) *Manual of Clinical Microbiology*. American Society for Microbiology, 8th Edition, ASM Press, Washington D.C. 2003
390. Weber R. Intestinal coccidia and microsporidia, p. 2425-2433. In: Cohen J, Powderly WG (eds.) *Infectious Diseases*, 2nd Edition. Mosby, London 2003
391. Weber R, Fontana A. Status febrilis, p. 108-205. In: W. Siegenthaler (ed.) *Differentialdiagnose innerer Krankheiten*. Georg Thieme Verlag, Stuttgart 2005
392. Weber R, Mathis A, Deplazes P. Microsporidia, p.2133-2143. In: Murray PR, et al. (eds.) *Manual of Clinical Microbiology*. American Society for Microbiology, 9th Edition, ASM Press, Washington D.C. 2007.
393. Weber R, Fontana A. Fever, p. 102-201. In: W. Siegenthaler (ed.) *Differential Diagnosis in Internal Medicine*. Georg Thieme Verlag, Stuttgart 2007
394. Weber R. Intestinal coccidia and microsporidia, p. 1876-84. In: Cohen J, Powderly WG (eds.) *Infectious Diseases*, 3rd Edition. Mosby Elsevier, London 2010.
395. Weber R, Deplazes P, Mathis A. Microsporidia, p. 2190-99. In: Murray PR, et al. (eds.) *Manual of Clinical Microbiology*. American Society for Microbiology, 10th Edition, ASM Press, Washington D.C. 2011.
396. Weber R, Fontana A. Status febrilis, p. 111-216. In: E. Battegay (ed.) *Siegenthalers Differentialdiagnose: Innerer Krankheiten – vom Symptom zur Diagnose*. Georg Thieme Verlag, Stuttgart 2012
397. Weber R, Deplazes P, Mathis A. Microsporidia, p. 2209-19. In: Murray PR, et al. (eds.) *Manual of Clinical Microbiology*. American Society for Microbiology, 11th Edition, ASM Press, Washington D.C. 2015.
398. Weber R. Intestinal coccidia and microsporidia, p. 1734-43. In: Cohen J, Powderly WG, Opal SM (eds.) *Infectious Diseases*, 4th Edition. Elsevier, London 2017.
399. Weber R, Fontana A, Schaer D. Status febrilis, p. 652-756. In: E. Battegay (ed.) *Siegenthalers Differentialdiagnose: Innerer Krankheiten – vom Symptom zur Diagnose*. Georg Thieme Verlag, Stuttgart, 2017.
400. Weber R, Deplazes P, Mathis A. Microsporidia, p. 2305-2316. In: Carroll KC and Pfaller MA (eds.) *Manual of Clinical Microbiology*. American Society for Microbiology, 12th Edition, ASM Press, Washington DC, 2019.

**F) Book**

401. Yu V, Weber R, Raoult D (eds.): Antimicrobial Therapy and Vaccines. Volume I: Microbes. Apple Trees Productions, New York 2002

**G) Various**

402. Cohen J, Carlet J for the INTERSEPT Study Group (1996) INTERSEPT: An international multicentre placebo-controlled trial of monoclonal antibody to human tumor necrosis factor- $\alpha$  in patients with sepsis. *Crit Care Med* 24:1431-40 [INTERSEPT Study Group, among other investigators: Weber R]
403. Mathis A, Weber R, Kuster K, Speich R (1996) Reliable one-tube nested PCR for detection and SSCP-Typing of *Pneumocystis carinii*. *J Eukaryot Microbiol* 43:7S
404. Robert-Koch-Institut (1996) Verfahrensrichtlinien für die Laboratoriumsdiagnostik von parasitären Infektionen beim Menschen. Empfehlungen zur Laboratoriumsdiagnostik von Infektionen mit Mikrosporidien. (verfasst von Weber R). *Bundesgesundhbl* 9/1996:363-5
405. Weber R, Pusterla N, Loy M, Lutz H (1998) Fever, leukopenia and thrombocytopenia in a patient with acute Lyme borreliosis was due to coinfection with Human Granulocytic Ehrlichia. *Clin Infect Dis* 26:253-4
406. Bryan RT, Weber R, Schwartz DA (1997) Microsporidiosis in persons without HIV. [Letter] *Clin Infect Dis* 24: 534-5
407. Weber R, Flepp M, Wichmann W (1997) Cerebral microsporidiosis due to *Encephalitozoon cuniculi*. [Letter] *New Engl J Med* 337:640-1
408. Weber R (1997) Die Kryptosporidiose bei immunkompetenten und immunkompromittierten Personen: Pathogenese, klinische Manifestationen und medizinische Bedeutung. *Schweizerischer Verein des Gas- und Wasserfaches* 23-26
409. Weber R, Fuchs KP, Jost J, Nadal D, Opravil M, Ott PM, Perruchoud A, Rued C, Steffen R, Zbinden R (1998) Antibiotika: Nutzen und Gefahren für Individuum und Gesellschaft (Teil 1). *Schweiz Ärztezeitung* 79:2307-10
410. Fuchs KP, Rued C, Weber R (1998). Antibiotikagebrauch und Resistenz: auch ein Problem in der ambulanten Praxis? (Teil 2). *Schweiz Ärztezeitung* 79:2401-2
411. Jost J, Weber R (1998) Gerechtfertigter oder ungerechtfertigter Einsatz von Antibiotika: wo liegen die Grenzen? (Teil 3). *Schweiz Ärztezeitung* 79:2506-7
412. Junghans C, Ledergerber B, Chan Ph, Weber R, Egger M (1999) Sex differences in HIV-1 viral load and progression to AIDS ? [Letter] *Lancet* 353:589
413. Weber R, Nadal D (1999) Ist die Antibiotikaresistenz übertragbar? (Teil 6) *Schweiz Ärztezeitung* 80:198-200
414. Nadal D, Weber R (1999) Diagnose und Therapie der akuten Tonsillopharyngitis durch Gruppe A  $\beta$ -hämolyisierende Streptokokken. (Teil 8). *Schweiz Ärztezeitung* 80:599-601
415. Morgan U, Xiao L, Sulaiman I, Weber R, Lal AA, Thompson A, Deplazes P (1999) Which genotypes/species of *Cryptosporidium* are humans susceptible to? *J Eukaryot Microbiol* 46:42S-43S
416. Weber R. Grippe bei Menschen und Hühnern im globalen Dorf: Zwischen Selbstgefälligkeit und Hysterie. *Schweiz. med. Forum* 2005;4:20-22.
417. Weber R (2006) Abklärung und Therapie der Lyme-Borreliose bei Erwachsenen und Kindern. Replik zu Letter to the Editor. *Schweiz. Ärztezeitung* 2006;87:298-299.
418. Schneider D, Nigg C, Käser L, Weber R (2008) [Complicated versus uncomplicated urinary tract infections] Komplizierte versus unkomplizierte Harnwegsinfektion. *CME Online-Fortbildung. PRAXIS* 97:925-34.
419. Haubitz S, Saur M, Weber R (2009) [Fever in returning travellers] Fieber bei Reiserückkehrern: Praktische Ratschläge zu einem effizienten Abklärungsgang. *CME Online-Fortbildung. PRAXIS* 98:303-311.



420. Kaiser P, Weber R, Rampini SK (2010). Akute Halsschmerzen. CME Online-Fortbildung. PRAXIS 99: 687–699.
421. Huber M, Kovari H, Weber R, Meerbach A (2010) Der besondere Fall: Eine besondere Gelbsucht. Swiss Medical Forum 2010;10(25):450–451
422. Huber M, Weber R, Beck B, Schweiger A, Grimm F (2010). Der besondere Fall: „Metastasenleber“ mit Eosinophilie. Swiss Medical Forum 2010;10:687–688.
423. Kovari H, Ledergerber B, Weber R. Idiopathic noncirrhotic portal hypertension in HIV-infected patients (letter, author reply). Clin Infect Dis 2010;50:128-9.
424. Kovari H, Ledergerber B, Weber R. Should HIV-infected patients with unexplained chronic liver enzyme elevations be tested for hepatitis E virus? Clin Infect Dis (letter, author reply) 2010;50:1546-7.
425. Wagner C, Preiswerk B, Weber R (2011) Images in Infection: Disseminated Kaposi sarcoma in newly diagnosed HIV. Infection 39:91
426. Bosshard PP, Graf N, Fröhlich Knaute D, Kündig T, Lautenschlager S, Weber R (2013) Response of Treponema pallidum Particle Agglutination Test Titers to Treatment of Syphilis. Clin Infect Dis [scientific letter] Clin Infect Dis 56:463-4.
427. Young J, Moodie EEM, Abrahamowicz M, Klein MB, Weber R, Bucher HC (2015) Incomplete modelling of the effect of antiretroviral therapy on the risk of cardiovascular events. Clin Infect Dis 61:1206-7. doi: 10.1093/cid/civ515
428. Weber R, Chmiel C. Infektiologie: Therapieempfehlungen. mediX Guideline, zuletzt revidiert: 06/2021, letzte Änderung: 06/2021
429. Weber R, Huber F. Migrationsmedizin. mediX Guideline, zuletzt revidiert: 10/2021, letzte Änderung: 10/2021
430. Weber R. Harnwegsinfekte Erwachsene. mediX Guideline, zuletzt revidiert: 12/2021, letzte Änderung: 12/2021
431. Weber R. Sexuell übertragbare Infektionen. mediX Guideline, aktualisiert: 03/2022.

#### H) Thesis Papers (Doctoral Thesis, Habilitation Thesis)

1. Weber R. Empirische Katamnese der Methadonbehandlung Opiatabhängiger bei Hausärzten im Kanton Zürich. Med. Diss. Zürich, 1983
2. Weber R. Die humanpathogenen Mikrosporidien. Habilitationsschrift, Zürich, 1993